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Clostridium difficile is a Gram-positive bacterium that causes a toxin-mediated 
disease, typically in individuals whose normal intestinal flora has been compromised by 
antibiotic therapy. C. difficile is naturally resistant to many antibiotics and produces 
spores that can withstand harsh environmental conditions and many disinfectants, 
making the infection difficult to clear and easy to spread. The infection begins when 
spores from the environment are ingested and germinate upon exposure to taurocholate 
and glycine in the digestive tract. This germination process is required to initiate 
infection and thus represents a good target for the development of novel therapeutics. 
Although spore germination is necessary for disease transmission, the molecular 
mechanisms regulating this process are poorly understood. Germination relies on 
sensing a germinant and triggering degradation of the cortex layer of the spore, which is 
important for spore resistance. Once the cortex is degraded, the spore can undergo 
outgrowth to a vegetative cell and secrete toxins to cause disease symptoms.  
 
There are several discrete steps to the proteolytic cascade that ultimately lead to 
cortex hydrolysis. First, the pseudoprotease CspC acts as a germinant receptor for the 
bile salt taurocholate; CspC then relays this signal to the subtilisin-like serine protease, 
CspB. CspB is required for efficient cleavage and activation of the cortex hydrolase. 
SleC. Upon proteolytic activation of SleC, cortex hydrolysis can proceed, which allows 
subsequent outgrowth. 
 
To better understand the mechanistic basis of the germination process, we 
solved the 1.6 Å structure of the required germination protease, CspB, from C. 
perfringens (a related pathogen). This structure revealed that CspB is comprised of 
three domains: an associated prodomain, a subtilase domain, and a jellyroll domain. 
Our work significantly advanced our understanding of the proteolytic cascade that leads 
to germination; in particular the structure and function of the CspB protease, and the 
role of its three domains. We have described the four domains of the cortex hydrolase, 
SleC, and how they contribute to the activity of SleC. We have recently obtained 
diffraction-quality crystals of the pseudoprotease, CspC, from an organism more 
closely related to C. difficile, C. bifermentans. Our latest work, focusing on the 
germination receptor, CspC, has brought us closer to a three-dimensional structure of 
this protein, which will likely reveal how it binds ligands and functions in germination. 
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CHAPTER 1: INTRODUCTION 
1.1. Clostidium difficile-associated disease 
The Gram-positive bacterium Clostridium difficile causes about 300,000 infections 
annually in the US, costing the health care system an estimated $2-5 billion per year, with 
each patient costing between $3,000 and $15,000[1, 2-4]. C. difficile is the leading cause 
of both antibiotic-associated diarrhea and hospital-acquired diarrhea in part because C. 
difficile is naturally resistant to many first line broad-spectrum antibiotics. Indeed, 
infections are often only symptomatic in individuals who have recently undergone 
antibiotic therapy. Diarrheal symptoms will often develop during, or up to a few weeks 
following, a course of antibiotics (clindamycin, metronidazole, penicillins, 
fluoroquinolones and cephalosporins have all been associated with subsequent first-time 
C. difficile infections) and worsen from mild to severe diarrhea[5]. Disease symptoms are 
caused by two toxins secreted by vegetative cells in the colon. The first, cytotoxic Toxin 
B, TcdB, requires access to the basolateral layer as receptors for its activity are only 
located there. The second, TcdA, Toxin A, an enterotoxin, does not have this requirement 
and it is thought to be the predominant toxin causing early symptoms, until more severe 
infection has allowed Toxin B to have an effect, though this is still debated[6-8]. 
However, TcdB alone is sufficient to cause disease symptoms and frequently, infective 
strains of C. difficile are found to express TcdB but not TcdA, though previous results 
have identified TcdA as more capable of causing inflammation, adding to the confusion[9, 
10]. The two toxins are the main virulence factors for C. difficile, but an additional toxin, 
CDT binary toxin, is one of several auxiliary virulence factors[6]. See Figure 1.6.1 for an 
illustration of a C. difficile infection in a human colon environment. 
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Infections are difficult to treat due to the natural resistance of C. difficile to many 
antibiotics and also its tendency to recur after the initial infection is treated[11]. The 
typical first choice in treatment of C. difficile infection is metronidazole (especially for 
mild-to-moderate disease) or vancomycin (for more severe disease)[12]. However, even 
with successful clearance of the infection following a course of broad-spectrum 
antibiotics, metronidazole or vancomycin will also disrupt the populations of many 
beneficial colonic commensals, leaving the individual with what is called a “permissive” 
colon, susceptible to recurrent infection, which occurs in 20-33% of cases, with more 
virulent strains associated with greater risk of recurrence[13]. Each re-infection leaves the 
patient more susceptible to future infections, often increasing in severity, and 3-6% of C. 
difficile infections will result in death[14]. Fidaxomicin is a newer macrocyclic drug with 
low absorption from the GI tract into the bloodstream (like vancomycin), high specificity 
for C. difficile, and limited activity against other species, making it much less disruptive to 
the colonic population[12]. Infections that are treated with fidaxomicin are significantly 
less likely to lead to recurrences[15-17]. Severe C. difficile infections (CDI) cause 
complications such as pseudomembranous colitis, toxic megacolon, and the most severe 
complication, fulminant colitis, which occurs in about 3% of CDI and often requires 
colectomy to treat[6, 18]. Recurrent C. difficile infections require different treatment 
approaches, and for the third and subsequent infections the treatment is different than 
standard treatment used during first and second infection[14, 19]. Fecal microbiota 
transplantation is now recognized as a treatment for recurrent C. difficile, with impressive 
cure rates as high as 90%[20]. Stool from a healthy donor can provide the microorganisms 
necessary to help restore colonic balance and prevent reinfection[6, 20-22].  
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1.2. The role of spores during C. difficile infections 
The ability of C. difficile to initiate disease depends on its ability to form the 
metabolically dormant spore-form[23]. This is because C. difficile is an obligate anaerobe 
and thus cannot survive in the presence of oxygen. C. difficile infections begin when 
spores are ingested by a susceptible individual and germinate in response to a specific bile 
salt, taurocholate, found in the large intestine. During normal C. difficile growth in the 
colon, the bacterium strongly induces sporulation, and the host excretes large amounts of 
spores in the fecal matter[24, 25]. Though the sigma factor signaling cascade required to 
complete sporulation has recently been delineated, it remains poorly understood how the 
sporulation pathway is initiated in C. difficile[24, 26]. Excreted spores can contaminate 
environments such as hospital rooms and persist despite environmental conditions and 
disinfection protocols, thus serve as important reservoirs for C. difficile[25]. 
Spores can persist for long periods of time due to their intrinsic resistance to many 
physical insults such as extreme pH and temperature shifts, boiling, and desiccation. This 
intrinsic resistance is partially due to the thick peptidoglycan cortex layer of the spore and 
their metabolic dormancy[27-29]. In studies evaluating hospital disinfection protocols, 
ethanol, HiBiscrub product, Steri-7, and related products were not successful disinfectants; 
effective disinfection requires 1% sodium hypochlorite solutions or 10% hydrogen 
peroxide, or products such as Spor-Klenz[27, 30]. Spores of Bacillus subtilis, considered a 
model organism for spore germination, have even been exposed to outer space and still 
been able to effectively germinate[31]. C. difficile can also infect some livestock and 
human companion animals, including sheep, pigs, hamsters and dogs. Furthermore, while 
no reports have implicated it as a food poisoning species, it has been found in up to 42% 
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of meat products (beef, pork, and turkey) in the USA[32]. Thus, it is entirely possible that 
it could be introduced to the colon by way of the food we eat[30, 33, 34]. The food 
ingestion route is difficult to prove as C. difficile is frequently found in the environment, 
and recently it has been shown that non-susceptible individuals can be colonized 
asymptomatically and they may act as carriers of the bacteria. Estimates for the numbers 
of asymptomatic carriers vary, but rates of carriage could be around 2-7% of the healthy 
population[35], higher in those that are hospitalized (~35%) or in long-term care facilities 
or extended hospitalization (~50%)[36, 37]. Many newborns are briefly colonized by C. 
difficile in the process of establishing colonic flora and estimates vary widely as to what 
percentage of babies are colonized by C. difficile, ranging from 2% to 90%[38-40]. It is 
thought that a transient C. difficile infection is a normal part of acquiring gut 
commensals[41-43]. By age three, children typically have acquired balanced and diverse 
microbiota, similar to that of adults., which is protective against C. difficile-associated 
disease. 
 
1.3. The role of the microflora in regulating C. difficile spore germination 
 
Normal human digestion requires large and varied populations of gut commensals, 
which live in the large colon and help to complete the digestive process by further 
breaking down the compounds that enter the large bowel from the small intestine. The 
human diet selects for the species of bacteria that live in the colon and can help the 
digestive process[44]. A disruption of this balanced microcosm (dysbiosis) can be brought 
on by use of antibiotics, or found in people with disrupted colonic microbial populations, 
such as those with inflammatory bowel diseases[45]. Studies have shown that patients 
  5 
with inflammatory bowel diseases are more likely to contract C. difficile infections due to 
the dysbiosis associated with the disease state and are more likely to have more severe 
outcomes during infection[45].  
Levels of the bile salt germinant taurocholate are elevated in the dysbiotic colon. 
Although C. difficile germinates in response to the bile salt taurocholate, in healthy 
individuals, taurocholate is quickly cleaved into its constituents, cholate and taurine, by 
resident bacteria[46]. Thus the presence of uncleaved taurocholate in the large bowel is 
thought to be the signal for C. difficile  of a dysbiotic colon and thus a suitable host[47-
49]. Additionally, C. difficile spore germination is inhibited by the presence of 
chenodeoxycholate, a bile acid with structural similarity to taurocholate, but produced in 
complex with amino acids and only acts as an inhibitor upon cleavage by resident 
microbes, contrary to signaling by taurocholate[46, 50-52]. Together these bile acids form 
a two-way system by which C. difficile can detect colons without a robust microbe 
population. C. difficile appears to favor a colonic environment  with reduced diversity, 
such as one that has been recently decimated by antibiotics, and into which only relatively 
few species have established themselves, since byproducts of limited bacterial metabolism 
seem to be associated with increased germination rates[53, 54]. A colon with a healthy 
microbiome will not only lack the germinant, it will also have the competitive inhibitor 
present in the same location. The process by which spores germinate is essential to 
infection[55] and thus a very important area for research in C. difficile pathogenesis. 
 
1.4. The molecular basis for spore germination in the Firmicutes 
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Spores consist of several discrete layers (see Figure 1.6.2 for an electron 
micrograph of dormant and germinating C. difficile spores; see Figure 1.6.3 for a cartoon 
drawing of a dormant C. difficile spore). The innermost layer, the core, contains the 
dehydrated and densely packed components required to become a vegetative cell. Outside 
of the core is an inner membrane consisting of largely immobile lipids that is impermeable 
to most small molecules, even water[56, 57]. The germ cell wall surrounds this membrane 
and will eventually become the cell wall of the new vegetative cell. Outside of these 
structures is a thick cortex composed of modified peptidoglycan. The cortex is believed to 
be the most important spore structure conferring resistance to physical insults. Outside of 
the cortex is outer membrane, which is surrounded by a proteinaceous coat and the 
outermost layer, the exosporium. There are many good reviews that describe the structural 
features of Clostridium difficile spores and the similarities and differences between C. 
difficile and the model organism for the spore-forming bacteria, Bacillus subtilis[25, 28, 
29, 58, 59]. Germination of spores can be thought of as two critical events: initiation of 
germination by sensing of a small molecule germinant, and hydrolysis of the cortex layer 
of the spore. Cortex hydrolysis must be tightly regulated to avoid loss of resistance in 
inhospitable environments as well as hydrolysis of vegetative cell peptidoglycan, which 
would cause lysis of the sporulating cell. 
Spores will only germinate in response to precise signals. Bacillus subtilis can 
germinate in response pressure, dipocolinic acid, or with small nutritional germinants such 
as sugars and amino acids, sensed via germination receptors (Ger family) found in the 
inner membrane of the spore[25, 56, 60].  Clostridium perfringens spores also germinate 
in response to amino acids and ions, specifically L-asparagine and potassium chloride 
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binding to Ger family receptors or detection of calcium dipocolinic acid, which is secreted 
by germinating spores[61].  
Germination initiation by Ger receptors involves release of calcium dipocolinic 
acid from the spore, and this release triggers cortex hydrolysis in both C. perfringens and 
B. subtilis[56]. It is interesting that calcium dipocolinic acid is released during 
germination, as both C. perfringens and B. subtilis spores will germinate in response to 
this, suggesting that germination of some spores will trigger germination of others. The 
Ger A and B receptors are located inside the spore along the inner membrane, with Ger C 
located more peripherally[56, 62]. However, no homologues to the Ger family of receptors 
are found in C. difficile and thus for a long time it was unknown how C. difficile could 
sense the germination signal[56, 63]. Activation of the cortex hydrolase must rely on some 
external signal, as discussed above, to avoid germination in inhospitable environments, 
but due to the lack of Ger receptors this initiation in C. difficile must happen differently 
than in B. subtilis or C. perfringens. 
Despite the lack of Ger receptors, cortex hydrolysis machinery appears to be fairly 
well conserved between C. perfringens and C. difficile. C. perfringens has two cortex-lytic 
enzymes, SleC and SleM, though only SleC is required for complete hydrolysis of the 
cortex, while SleM degrades the leftover fragments[64]. SleC consists of four domains 
and exists in spores as an inactive zymogen, pro-SleC, requiring activation by a 
germination-specific protease to become an active hydrolyase[61].	  	  
Shio Makino’s group published most of the foundational work on spore cortex 
lytic enzymes in Clostridium perfringens, beginning in the mid 1990s, when they 
identified an enzyme that was released during germination of Clostridium perfringens 
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spores[65]. They were the first to discover and report that SleC in C. perfringens was 
produced in a pre-pro-form and is inactive in the dormant spore due to the associated 
prodomain[66]. This was demonstrated by Western blotting using antibodies against SleC: 
in dormant spores, a 36-kD protein was present, and in germinating spores there were both 
the 36-kD protein and a smaller 31-kD protein[66]. A few years later they were able to 
demonstrate that, in addition to the pre-domain associated only in sporulating cells, SleC 
includes an extended C-terminal sequence of about 25 amino acids, which is also 
processed during sporulation, and they suggested that either or both of these could be 
required for proper translocation to the outer layers of the cortex during spore 
formation[67]. Thus, when spores of C. perfringens are completely formed but have not 
yet received signal to germinate, SleC is located in the outer region of the cortex (as 
shown by Miyata et al. using colloidal gold particles[68]) and exists in a form containing a 
35-amino acid propeptide as well as the 264-amino acid hydrolase domain[67] but from 
which the 115-amino acid predomain, and the 25-amino acid C-terminal extended 
sequence (called a C-terminal prosequence in some literature), have both been 
cleaved[66]. From this stage, activation of SleC is required, by way of cleavage of the 
inhibitory prodomain.  
Activation of SleC will result in cortex hydrolysis, core hydration and expansion, 
and eventually outgrowth to a vegetative cell. Makino’s group then demonstrated both that 
the N-terminal 115-amino acid predomain, though cleaved, remains associated with the 
pro-SleC under non-reducing conditions (predomain-pro-SleC), and that the predomain 
has both stabilization and chaperone effects, being required for proper folding and 
thermostability of the enzyme and preventing pro-SleC—pro-SleC dimerization[69].  At 
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this point, they hypothesized that the function of the predomain is in folding and stability, 
and the function of the propeptide is in enzyme inhibition, until an activation signal is 
received and cleavage of the prodomain occurs[69]. SleC expression, processing and 
regulation is in contrast to the cortex fragment-lytic enzyme, CFLE, called SleM in C. 
perfringens, which is produced and exists in dormant spores in its mature, active form[64, 
67]. Though it exists in an active form in dormant spores, SleM’s cortex-fragment 
substrate is not present until after SleC has begun cortex hydrolysis[64, 67].	  
The germination-specific protease (GSP) implicated in germination was thought to 
be responsible for the cleavage and activation of SleC[67]. Most strains of C. perfringens 
encode three such germination-specific subtilisin-like serine proteases, CspA, CspB and 
CspC[70]. In 2001 it was shown that purified GSPs (containing CspA, CspB, and CspC), 
when incubated with the predomain-pro-SleC complex, were able to generate active SleC 
enzyme with a molecular weight of 31 kD by cleaving between Val-149 and Val-150 in 
the junction between the prodomain and the SleC hydrolase[71]. Thus, the Csps are 
required for activation of the SleC cortex hydrolyase, downstream of detection of 
germinants, though it is not yet completely understood how the signal passes between 
sensing germinants and activation of Csps. In C. perfringens, only CspB is required for the 
activation of SleC, while CspA and CspC are thought to have the same, if redundant, 
function[56, 70, 72]. Until recently, very little was known about germination in C. difficile 
though the process was thought to be similar to germination in C. perfringens and other 
related species. 
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1.5. The molecular basis for C. difficile spore germination 
 
Notably, C. difficile lacks ger family receptors, as previously discussed, making it 
unclear how the germination cascade begins in a new infection. Bile acids have been 
implicated for almost 40 years in causing germination of C. difficile isolates[49], and later 
it was discovered that taurocholate was the specific bile acid that spores responded to, in 
combination with glycine or other amino acids[73]. It was demonstrated a few years ago 
that germination in C. difficile proceeds at a rate suggestive of a specific germinant 
receptor, while a genetic screen enabled identification of CspC as the specific protein 
required[47, 74]. Several single amino acid substitutions within CspC rendered C. difficile 
unable to respond to taurocholate[47]. CspC is a subtilisin-like pseudoprotease, whose 
family members CspA and CspB are implicated in the germination cascade as activating 
the germination-specific cortex hydrolase SleC, required for germination. Unlike C. 
perfringens and other Clostridium spp. [75], C. difficile CspA and CspC each contain two 
single amino acid substitutions within their catalytic triads that render them inactive[76]. 
Only CspB retains its protease activity[76], but C. difficile CspB is expressed as a fusion 
to catalytically-inactive CspA, an arrangement only observed in other 
Peptostreptococcaceae family members, while organisms that possess three active Csps 
typically express them as separate polypeptides[75].While CspC and CspA did not have 
any known function, they still were required for germination, as shown by our lab and 
others[47].  
The concept of pseudoproteases has recently been found in many different 
biological pathways[77-79]. Often, these catalytically dead proteins are as essential as 
  11 
their active counterparts, and often, a single amino acid substitution interrupts the activity, 
while retaining the overall structure of the protein, pseudoproteases could play a role in 
regulation— substrates still bind in the substrate binding cleft, but they cannot be 
cleaved[77-79].  
It has not yet been observed whether germinants are able to directly bind CspC or 
if an intermediate is needed. Additionally, while it is thought that the germination signal is 
relayed through CspC’s sensing of germinant, activation of CspB, and CspB’s activation 
of inactive SleC and the initiation of cortex hydrolysis, none of these interactions have 
been structurally observed.  
We sought to use X-ray crystallographic studies to determine the three dimensional 
structure of the key players in the germination cascade and use this information to guide 
future studies that could demonstrate their interaction or illustrate the signaling cascade at 
a molecular level. We were able to determine the crystal structure of CspB from 
Clostridium perfringens to 1.6 Angstroms (Å) and learn about function from form[76], 
and have made strides towards the structure of CspC from closely-related Clostridium 
bifermentans (unpublished data), which we hope to be able to crystallize in complex with 
associated germinant or inhibitor to observe how these interactions take place.  
A close understanding of this process could aid in design of therapeutics, as the 
ability to influence germination could control infections, as germination is required to 
begin infection. Structure-based drug design is a burgeoning field and these methods could 
be applied for the treatment of Clostridium difficile infections, with control of germination 
being a suitable target for therapeutic development. 
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1.6. Figures 
 
Figure 1.6.1. Schematic of colonic lumen during Clostridium difficile infection. 
Illustration of the colonic epithelium in a C. difficile patient, displaying 
germination of spores, toxin production, effects of toxins and formation of 
pseudomembrane; sporulation and transmission of spores. This figure was adapted from 
Shen 2012[9]. 
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Figure 1.6.2. Scanning electron micrographs of dormant and germinating spores. 
 (A): A scanning electron micrograph of a dormant C. difficile spore. Components 
of the spore as discussed in the text are labeled. (B) Scanning electron micrograph of a 
germinating C. difficile spore, fixed for imaging 10 minutes after germinant was added. 
Thinning of cortex layer and expansion of core are visible. Labeled components of the 
spore as above. Images credit: Emily Putnam. 
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Figure 1.6.3. Cartoon representation showing layers of the spore. 
Cartoon representation illustrating the layers of a C. difficile spore, as discussed in 
the text. Spore core, central, shown as a deep gray, surrounded by the inner spore 
membrane and the germ cell wall, each shown as a black line. The cortex, shown in a pale 
tan color, is outside of the three inner structures, and inside of the outer spore membrane 
and the proteinaceous coat. The exosporium is not pictured, but is an additional loose-
fitting layer outside of the spore coat. 
 
  
  15 
 
Figure 1.6.4. Standard and proposed reclassification of C. difficile 
The standard classification of C. difficile, shown in the top panel, was order 
Clostridiales, family Clostridiaceae, genus Clostridium and many species were included 
within this genus, some quite distantly related. A proposed reclassification, shown in the 
lower panel, suggested by Yutin et al.[75], adds the family Peptostreptococcaceae, and the 
genus Peptoclostridium to include the species difficile, bifermentans, sordellii, and 
bartlettii, among others, while some Clostridium spp. remain as they were previously 
classified, including the species perfringens, tetani, butyricum, and botulinum, among 
others. 
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CHAPTER 2: STRUCTURAL AND FUNCTIONAL ANALYSIS OF THE CspB 
PROTEASE REQUIRED FOR CLOSTRIDIUM SPORE GERMINATION 
2.1. Introduction 
The Gram-positive, spore-forming obligate anaerobe Clostridium difficile is the 
leading cause of nosocomial diarrhea worldwide [11, 80, 81]. The symptoms of C. 
difficile-associated disease (CDAD) range from mild diarrhea to pseudomembranous 
colitis and even death. Although CDAD is primarily a toxin-mediated disease [9, 81], the 
high cost and difficulty in treating C. difficile infections largely arises from its ability to 
form endospores [82, 83]. Because spores are metabolically dormant and intrinsically 
resistant to harsh physical insults [27, 28, 59, 81], they allow C. difficile to resist antibiotic 
treatment and persist in healthcare-associated settings. Thus, spores are the primary 
vectors for transmission [23] and the cause of recurrent infections, the latter of which 
occurs in ~25% of cases and can lead to severe CDAD [83, 84].  
In order to initiate an infection, C. difficile spores ingested from the environment 
must germinate into toxin-producing vegetative cells in the intestinal tract [11, 81, 85]. 
Similar to other spore-forming bacteria, C. difficile spores germinate specifically in 
response to small molecules known as germinants [56, 86]. For C. difficile, these 
germinants are bile salts, which are abundant in the small intestine [48, 50, 55]. While 
germinants have been identified for a number of bacterial species, the molecular events 
that occur upon germinant sensing remain poorly characterized [56, 86, 87]. Shortly after 
germinant addition, cortex hydrolases become activated and degrade the spore cortex, a 
thick protective layer of modified peptidoglycan. Because the cortex maintains the spore 
in a dehydrated, metabolically dormant state, the removal of this physical constraint is 
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essential for germination to proceed and metabolism to resume in the spore core [56, 86, 
87]. Nevertheless, despite the importance of cortex hydrolysis, little is known about the 
molecular mechanisms that regulate cortex hydrolase activity. 
In the Clostridia, the primary cortex hydrolase appears to be SleC, since disruption 
of sleC in both C. difficile [88] and the related foodborne pathogen C. perfringens [89] 
results in a severe germination defect. In C. perfringens, SleC undergoes several 
processing events. During sporulation, the N-terminal prepeptide is removed to produce 
pro-SleC, which consists of an N-terminal propeptide attached to the hydrolase domain 
[65-67, 90]. During germination, the zymogen pro-SleC is cleaved at a conserved site to 
release the propeptide (Figure 1A); this event appears to activate its hydrolase activity [65, 
91].  
Biochemical analyses of C. perfringens germination exudates have shown that a 
fraction containing three serine proteases (CspA, CspB, and CspC) can proteolytically 
activate SleC hydrolase activity in vitro [91]. CspB alone appears sufficient to activate 
SleC, since the food-poisoning isolate SM101 encodes only the cspB gene, and disruption 
of this gene abrogates SleC cleavage and spore germination [70]. In the genome of C. 
difficile, three csp homologs are present in a bicistronic operon (cspBA-cspC, Figure S1), 
with cspB and cspA being present as a gene fusion [56]. Since disruption of the cspBA-
cspC operon by transposon insertion results in a severe germination defect [92], cortex 
hydrolysis in C. difficile and C. perfringens would appear to be similarly regulated. 
While studies have shown that SleC and CspB are key players during germination, 
the molecular mechanisms regulating their function are unknown. The sequence homology 
between Csp proteases (Csps) and the subtilase protease family [91] provides a starting 
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point for understanding how Csps transduce the germination signal and activate SleC. 
Subtilases are serine proteases that contain a catalytic triad in the order of Asp, His and 
Ser [93, 94], and most subtilases are produced as pro-enzymes that autoproteolytically 
remove their prodomain [93, 95, 96]. While Csps purified from C. perfringens 
germination exudates are N-terminally processed [91], whether Csps are regulated in a 
manner analogous to other subtilases is unclear. Indeed, whether Csps actually have 
protease activity has not yet been directly demonstrated. 
In this study, we investigated the protease activity of CspBA in C. difficile. By 
analyzing CspBA in sporulating C. difficile and purified spores, we demonstrate that 
CspBA is processed to CspB during spore assembly and that CspB undergoes 
autoprocessing. We also present the first crystal structure of the conserved Csp family of 
proteases at 1.6 Å resolution and define its key structural domains. These biochemical and 
mutational analyses reveal that, in contrast to previously characterized prokaryotic 
subtilases, wildtype CspB forms a stable complex with its prodomain. Similar to other 
subtilases [96], the prodomain acts as both an intramolecular chaperone and an inhibitor of 
CspB protease activity. These findings provide the first molecular insight into Csp 
function and may inform the development of strategies that can either prematurely activate 
C. difficile spore germination in the environment or prevent spore germination during 
disease transmission and recurrence. 
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2.2. Materials and Methods 
2.2.1. Bacterial growth conditions 
Bacterial strains and plasmids used in this study are listed in Table S2 in Text S1. 
The C. difficile strains are isogenic with the erythromycin-sensitive strain JIR8094 [97], a 
derivative of the sequenced clinical isolate 630 [63]. C. difficile strains from freezer stocks 
were grown on BHIS agar plates [98] supplemented with and 0.1% sodium taurocholate 
(BioSynth International). To induce sporulation, C. difficile strains were grown on 70:30 
agar plates (63 g BactoPeptone, 3.5 g Protease Peptone, 11.1 g BHI, 1.5 g yeast extract, 
1.1 g Tris base, 0.7 g NH4SO4 per liter). Media for C. difficile were supplemented with 10 
µg thiamphenicol (Thi) mL-1, 50 µg kanamycin (Kan) mL-1, 8 µg mL-1 cefoxitin (TKC); 
10 µg thiamphenicol mL-1; or 5 µg erythromycin mL-1 (Erm) as needed. C. difficile strains 
were maintained at 37˚C in an anaerobic chamber (Coy Laboratory Products) with an 
atmosphere of 10% H2, 5% CO2, and 85% N2.  E. coli strains were grown at 37ºC in 
Luria-Bertrani (LB) broth.  Antibiotics were used at 100 µg mL–1 carbenicillin for 
pET22b, 30 µg mL–1 kanamycin for pET28a, and 20 µg mL-1 chloramphenicol for 
pMTL83151 and pMTL84151 vectors in DH5α E. coli strains, and 100 µg mL-1 and 20 µg 
mL-1 in HB101 E. coli strains.  
 
2.2.2. Sporulation Assay 
C. difficile strains were inoculated from frozen stocks onto BHIS plates containing 
0.1% taurocholate. After 24 hr growth, a heavy streak of the strain was transferred to a 
70:30 plate and spread uniformly across the plate. Whereas <0.1% of cells are sporulating 
on BHIS plates [2], ~25% of cells undergo sporulation at the timepoints analyzed in this 
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study as determined by phase-contrast microscopy similar to Burns et al. [85] (Figure 1C). 
While the induction of sporulation occurs at different rates within the population, this 
assay allows us to produce relative high rates of sporulating cells. At the indicated 
timepoints, cells were scraped from the plate and resuspended in PBS. The cells were 
pelleted and then resuspended in PBS. For Western blot analysis, 50 µL of the cell 
resuspension was removed, and the sample was frozen at -80˚C. The remainder of the 
sample was analyzed by phase contrast microscopy to assess the progression of 
sporulation. 
 
2.2.3. Preparation of C. difficile samples for Western blot analysis 
For sporulating C. difficile samples, cell pellets harvested from the sporulation 
assay were subject to three cycles of freeze-thaw. On the final thaw, 100 µL of EBB 
buffer (9 M urea, 2 M thiourea, 4% w/v SDS, 10% v/v β-mercaptoethanol) was added, and 
the sample was boiled with occasional vortexing for 20 min. The lysate was pelleted for 5 
min at 13,000 x g and then resuspended; 7 µL of 4X loading buffer (40% v/v glycerol, 0.2 
M Tris pH 6.8, 20% v/v β-mercaptoethanol, 12% SDS, 0.4 mg/mL bromophenol blue) 
was added. The sample was boiled again for a minimum of 5 min, pelleted at 13,000 x g, 
and 15 µL was resolved on a 7.5% (for analysis of CspB in sporulating cells) or an 11 or 
12% SDS-polyacrylamide gel (for analyses of purified spores). 
For analyses of purified spores, ~5 x 106 spores were pelleted at 15,000 x g for 5 
min. The spore pellet was resuspended in 50 µL EBB buffer, boiled for 20 min with 
periodic vortexing, pelleted at 13,000 x g for 5 min, and resuspended to further solubilize 
proteins. Five µL of 4X loading buffer was added, and the sample was boiled for 5 min. 
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After pelleting at 13,000 x g, 10-15 µL of the sample was resolved on an 11% or 12% 
SDS-polyacrylamide gel. 
 
2.2.4. Western blot analysis 
All antibodies used in this study were raised in rabbits by CoCalico Biologicals, 
with the exception of the SleC antibody, which was raised in rabbits by Pacific 
Immunology. The antigens used were His6-tagged CspB(1-548 aa), full-length His6-tagged 
CspB perfringens, His6-tagged CspC, His6-tagged SleC and His6-tagged CD1433. 
Samples resolved by SDS-PAGE were transferred to Immobilon-FL PVDF membranes 
(Millipore). The membranes were blocked in 50:50 PBS:LiCOR blocking buffer (LiCOR) 
for 30 min, after which Tween 20 was added to 0.1% v/v, and polyclonal antisera was 
added at 1:1,000 for all antibodies with the exception of the anti-SleC antibody, which 
was used at a 1:5,000 dilution. After a minimum of 1 hr incubation with shaking, the 
membranes were washed a minimum of 3 times in PBS+0.01% v/v Tween. Anti-rabbit 
secondary antibodies conjugated to IR800 dye (LiCOR) were added at 1:30,000 dilution in 
50:50 PBS:LiCOR blocking buffer containing 0.1% v/v Tween and 0.1% v/v SDS then 
incubated with shaking for 1 hr. The membranes were washed a minimum of 3 times in 
PBS+0.1% v/v Tween before imaging on an Odyssey Clx scanner (LiCOR). Western blot 
quantitation was performed using the indicated loading controls and LiCOR ImageStudio 
software. 
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2.2.5. Purification of C. difficile spores 
Sporulation was induced for 3 - 4 days on five 70:30 plates. Spores and cell debris 
were scraped off the plate into 1 mL ice-cold sterile water and purified as previously 
described [98]. Briefly, the sample was subjected to 5 washes in ice-cold sterile water, 
followed by a HistoDenz gradient purification and 3-5 washes in ice-cold sterile water. 
Spores were stored at 4˚C in water. 
 
2.2.6. Germination assay 
Purified spores were enumerated using disposable semen test counting chambers 
(InCyto C-Chip). Approximately 5 x 107 spores were resuspended in a total volume of 100 
µL sterile H2O. The spores were heat activated at 60˚C for 30 min, cooled for 2 min on 
ice, then 100 µL of 2X BHIS was added. 100 µL of the spores were removed to a tube 
containing 2 µL of 10% sodium taurocholate to induce germination. Both samples were 
incubated at 37˚C for 20 min after which spores were serially diluted 10-fold into PBS. 10 
µL of the dilutions was spotted onto either BHIS or BHIS + 0.1% taurocholate agar plates 
in triplicate and incubated anaerobically at 37˚C for ~24 hr before assessing spore 
viability. Equivalent numbers of viable spores were recovered on untreated spores plated 
on BHIS + 0.1% taurocholate plates and taurocholate-treated spores plated on BHIS or 
BHIS + 0.1% taurocholate plates. Because spore clumping increased the variability in 
counting spores, CD1433 [99] was used as a loading control in some Western blot 
analyses. 
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2.2.7. Crystallization 
Appropriate protein concentrations for crystallization were determined using Pre-
Crystallization Test (Hampton Research, Aliso Viejo, CA). Hanging drop crystallization 
experiments were conducted with CspB (11 mg/mL) in 150 mM NaCl, 10 mM Tris-HCl 
pH 7.5 and Crystal Screen 2 (Hampton Research). Crystal trays were incubated at 12˚C 
and initial crystal hits in 25% (v/v) ethylene glycol (Condition 3) were discovered within 
24 hours. After refinement of crystallization conditions, crystals grew reproducibly to 
about 100*250*60 µm3 in 27-30% (v/v) ethylene glycol buffered to pH 5 with 50 mM 
sodium acetate. Crystals grew in space group P212121, with unit cell dimensions a = 73.87, 
b = 138.17, and c = 140.08 Å and two molecules in the asymmetric unit for an estimated 
57% solvent content [100-102]. As crystallization conditions contained sufficient ethylene 
glycol to serve as a cryoprotectant, crystals were flash cooled in liquid nitrogen directly 
from the crystallization drop. 
 
2.2.8. Data Collection 
A complete 1.6 Å single-wavelength data set of a representative selenomethionyl-
CspB crystal was collected at the selenium edge (0.9794 Å) at 100 K at the General 
Medical Sciences and Cancer Institutes Structural Biology Facility (GM/CA @ APS) 
beamline 23ID-B at the Advanced Photon Source, Argonne National Laboratory 
(Chicago, IL, Table S4 in Text S1). 
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2.2.9. Data Processing 
Data were processed using Denzo and Scalepack [103].  Twelve selenium sites 
were expected, from 6 methionines in the protein sequence and two predicted molecules in 
the asymmetric unit, using the Matthews Coefficient program [100, 101] in the CCP4 
Program Suite [102]. ShelXC/D/E, also part of the CCP4 Suite, was used to identify the 
selenium sites and gain initial phase information [102, 104, 105]. The 12 selenium sites 
and phase information were used in ShelX/E for density modification and generation of 
the initial phased map (Fig. S7) [104, 105]. 
 
2.2.10. Structure Solution and Refinement 
The initial model was produced by Phenix.AutoBuild using input phases from 
ShelX/E [104, 106]. Manual building was performed into the original phased map to 
reduce model bias. Refinement of the structure was done with manual building and 
adjustment in COOT [107] and refinement of the latest iteration of the model using 
Phenix.Refine [106]. All protein and ligand (non-water) B-factors were refined 
anisotropically. Phenix.AutoBuild with simulated annealing was used after multiple 
rounds of refinement to gain density for some poorly-resolved loops in the structure, 
resulting in the placement of several previously missing residues [106]. Ten percent of 
reflections were set aside for Rfree calculation. Model was refined to an Rwork/Rfree of 
0.15/0.18 and Ramachandran statistics were 97.9% in favored regions and 2.1% in 
allowed regions, with no Ramachandran outliers. 957 water molecules were placed by 
Phenix.Refine and checked with the Check Waters feature in COOT [106, 107]. 
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Although CspB is a dimer in the asymmetric unit, gel filtration chromatography 
experiments (see Text S1) indicate that CspB is a monomer in solution. In monomer 1, 
five residues were not built due to disorder in the electron density map (residues 411-415); 
in monomer 2, three residues were not built due to disorder (residues 411-413). These 
residues are part of a small loop located between two strands of the jellyroll domain. 
Additionally, the first four residues (residues 1-4) of the prodomain in each monomer 
were disordered and not built. Electron density for the C-terminal His6-tag used for protein 
purification (see Text S1) was seen in the second monomer only; these residues were 
stabilized by a crystal-packing interface, thus enabling residues 566-573 to be built in this 
monomer. Although the presence of calcium in the model was expected because this metal 
is present in many subtilisin family members [96], elemental analysis did not detect Ca2+ 
in our enzyme preparation (Dartmouth Trace Elemental Analysis Lab, data not shown). 
Two putative Na+ and three Cl- atoms (confirmed by sodium iodide soaks) were placed in 
the model, in addition to ethylene glycol, a crystallization reagent. 
 
2.2.11. Limited Chymotrypsin Proteolysis 
Wildtype CspB and its mutant variants were diluted to 15 µM in 10 mM Tris pH 
7.5 buffer in a total volume of 150 µL. Twenty-four microliters of the mixture were 
transferred into 8 well strip tubes. One microliter of chymotrypsin (Sigma, 25-fold 
concentrate relative to indicated concentration) was added, and the mixture was mixed 
then incubated for 60 min at 37˚C. Chymotrypsin activity was quenched by the addition of 
8 µL of 4X loading buffer. The samples were boiled for 3 min at 95˚C and then 7 µL was 
resolved on a 15% SDS-PAGE gel and visualized by Coomassie staining. 
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2.2.12. Preparation of E. coli samples for Western blot analysis 
E. coli cultures were grown as described for protein purification. One hour after 
IPTG induction, a 1 mL sample was removed, the OD600 measured, and the sample 
pelleted at 13,000 x g for 2 min. Cells were lysed in 1X loading buffer (10 OD600/mL). 
To obtain cleared lysate samples, 30 µL of the supernatant produced upon high-speed 
centrifugation of sonicated lysates was added to 10 µL of 4X loading buffer. For eluate 
samples, 30 µL of the eluate was added to 10 µL of 4X loading buffer. All samples were 
boiled at 95˚C for 5 min, pelleted at 13,000 x g for 5 min, then 2.5 µL of induced and 
cleared lysate samples or 5 µL of eluate samples were resolved on a 12% SDS-PAGE gel 
and analyzed by Western blotting. 
 
2.2.13. Activity-based probe labeling of CspB perfringens 
Wildtype CspB and its mutant variants were diluted to 10 µM in 10 mM Tris-HCl 
pH 7.5 buffer in a total volume of 155 µL. Twenty-five microliters were aliquoted in 
triplicate into strip tubes. 0.25 µL of 100 µM FP-Rh (fluorophosphanate-rhodamine probe) 
was added to CspB and incubated at RT for 10 min. Labeling was quenched by adding 8 
µL 4X loading buffer to the sample and boiling at 95˚C for 3 min. Six microliters of the 
labeling reaction was resolved on a 15% SDS-PAGE gel, and fluorescence was imaged 
using a Biorad PharosFX scanner. 
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2.2.14. Accession codes 
Coordinates and structure factors have been deposited in the Protein Data Bank 
(www.rcsb.org) under the accession number 4I0W. 
 
2.3. Supporting Materials and Methods 
2.3.1. Strain and plasmid construction for genetic manipulation of C. difficile.  
Oligonucleotides used in this study are listed in Supporting Table 3. C. difficile 
strain 630 DNA was used as a template for PCR amplification. Sequencing was performed 
at the University of Vermont DNA Analysis Core Facility. To construct the null mutation 
in the cspBAC locus, the ClosTron method for targeted gene disruption in C. difficile [108, 
109] was used. A modified plasmid containing the retargeting group II intron, pCE240 (a 
gift from C. Ellermeier, University of Iowa), was used as the template with primers #533, 
534, and 535 and the EBS Universal primer (#532), as outlined in the TargeTron users’ 
manual (Sigma Aldrich). The resulting retargeting sequence was digested with 
BsrGI/HindIII and cloned into pJS107 (a gift from J. Sorg, University of Texas A&M), 
which is a derivative of pJIR750ai (Sigma Aldrich) with similarity to pMTL007 [108, 
109]. The resulting plasmid pJS107-cspBAC-81 was transformed into HB101/pRK24 [97] 
for conjugation into JIR8094 to generate cspBAC–. Specifically, the E. coli donor strain 
was grown aerobically in 2 mL of LB supplemented with ampicillin and chloramphenicol 
until early stationary phase. The culture was pelleted gently at 2,500 x g for 5 min, and the 
resulting pellet was transferred into the anaerobic chamber. The pellet was resuspended in 
1 mL of a C. difficile recipient strain grown anaerobically in BHIS at 37˚C with slow 
shaking until early stationary phase. 100 µL of the cell mixture was spotted onto a single 
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BHIS agar plate and incubated overnight for 14 – 18 hr after which the cells were scraped 
into 2.5 mL BHIS. Seven 100 µL drops of the mixture were spotted onto three BHIS/TKC 
plates. Thiamphenicol-resistant colonies typically appeared with 30 – 48 hr, after which 
they were streaked onto BHIS plates containing Thi, Kan and 50 µM FeSO4. This step 
induces the ferroredoxin promoter that controls the expression of the group II intron. The 
resulting streaks were transferred to BHIS-Erm plates; Erm-resistant colonies typically 
appeared after 48 hr, after which they were struck to single colonies then screened by PCR 
using primers #457 and 538, the latter of which binds within the pJS107 vector. 
To complement the targetron disruption of cspBAC, a 5364 bp fragment containing 
the cspBAC operon and its upstream region was amplified using primers #691 and 665. 
The resulting PCR product was digested with NotI-HF and XhoI (New England Biolabs) 
and ligated into pMTL83151 [110]. The S461A mutation was introduced using PCR 
splicing by overlap extension (SOE) [111]. Primer pair #691 and 464 were used to amplify 
the 5’ SOE product, while primer pair #665 and 465 were used to amplify the 3’ SOE 
product. The resulting fragments were mixed together, and the flanking #691 and #665 
primers were used to amplify the 5364 bp S461A fragment. The ∆jelly mutation 
(corresponds to deletion of aa 260-392) was constructed similar to the S461A mutation, 
with the exception that the internal SOE primers were #746 (used with #691) and #745 
(used with #665). All complementation plasmids were transformed into HB101/pRK24, 
and the conjugation was performed as described except that after 14 hr incubation on non-
selective media, the bacterial mixture was scraped into 1 mL PBS. 100 µL of the mixture 
was spotted onto a total of five BHIS-TKC plates. Thiamphenicol-resistant colonies 
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typically appeared after 48 hr incubation, after which they were re-streaked to single 
colonies. At least two independent clones of each strain constructed were analyzed. 
The sleC mutant was constructed as previously described by Burns et al. [88] 
using primers #641, 642, and 643, with the exception that pJS107 was used for the 
targeting vector. Primer pair #461 and 463 were used to screen colonies for clones 
containing the targetron insertion. 
To construct cspBAC pMTL84151 complementation constructs, PCR SOE was 
used to introduce the following sequence, TAGGAGGGATTTATG between the codons 
for Gln66 and Asp70. This sequence is derived from the end of the cspBA gene, including 
the stop codon, and the start of the cspC gene, including the start codon. Insertion of this 
sequence results in the introduction of a stop codon, ribosome binding site and start codon 
in between the codons for Gln66 and Asp70. In particular, primers #691 and #951 were 
used to amplify the 5’ SOE product, while primers #864 and #950 were used to amplify 
the 3’ SOE product using either pMTL83151-cspBAC or pMTL83151-cspBAC S461A as 
the PCR template. The resulting fragments were mixed together, and the flanking #691 
and #864 primers were used to amplify a 2790 bp fragment. The fragment was gel-
purified, digested with NotI and KpnI and ligated to gel-purified pMTL83151-cspBAC 
digested with the same enzymes. The resulting pMTL83151-Q66 and Q66/S461A 
plasmids were used as PCR templates for a second PCR reaction, this time using primers 
#691 and #665. The resulting PCR fragment was gel purified, digested with NotI and 
XhoI, and ligated to pMTL84151 digested with the same enzymes. The pMTL84151 [110] 
multicopy vector was used for the transcomplementation because expression of the split 
prodomain constructs from the pMTL83151 multicopy vector resulted in lower levels of 
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CspBA relative to wildtype (data not shown). This observation likely reflects a reduced 
efficiency in prodomain intermolecular chaperone activity relative to intramolecular 
chaperone activity. pMTL84151 plasmids were conjugated into C. difficile using the same 
method as conjugating pJS107 plasmid constructs. 
 
2.3.2. Construction of CspB constructs for recombinant protein purification.  
Primers used are listed in Supporting Table 1; strains and plasmids constructed are 
listed in Supporting Table 2. To construct a strain producing recombinant CspBA (1-548 
aa, expression construct used for antibody production), primers #457 and #459 were used 
to amplify the sequence encoding amino acids 1- 548 of CspBA from C. difficile 630 
genomic DNA. The amplified DNA was digested with NcoI and XhoI, ligated to pET28a, 
and transformed into DH5α. The resulting pET28a-cspB(1-548 aa) plasmid was 
transformed into BL21(DE3). To mutate the catalytic Ser of CspBA, PCR SOE was used 
to introduce the S461A catalytic Ser point mutation into pET28a-cspB(1-548 aa). Primers 
#457 and 465 were used to amplify a 5’ fragment, and primers #459 and #464 were used 
to amplify a 3’ fragment. The resulting fragments were used as the templates for a second 
PCR reaction using the flanking primers, #457 and #459, to amplify cspB(1-548 aa) 
carrying the S461A mutation. A similar strategy was used to mutate the P3-P1 residues of 
CspBA to produce plasmid pET28a-cspB(1-548)-QTQ/AAA, with the exception that the 
SOE primers were #502 and #503. 
To construct a cd1433 expression construct for antibody production, primers #522 
and #523 were used to amplify the cd1433 gene lacking the stop codon. The resulting 
PCR product was digested with NcoI and XhoI, ligated to pET28a, and transformed into 
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DH5α. The resulting pET28a-cd1433 plasmid was transformed into BL21(DE3). To 
construct a sleC expression construct for antibody production, primers #461 and #463 
were used to amplify the sleC gene lacking the stop codon. The resulting PCR product 
was digested with NdeI and XhoI, ligated to pET22b, and transformed into DH5α. The 
resulting pET22b-sleC plasmid was transformed into BL21(DE3). To construct a cspC 
expression construct for antibody production, primers #524 and #525 were used to amplify 
the cspC gene lacking the stop codon. The resulting PCR product was digested with NdeI 
and XhoI, ligated to pET22b, and transformed into DH5α. The resulting pET22b-cspC 
plasmid was transformed into BL21(DE3). 
To construct a strain producing recombinant CspB perfringens, primers #512 and 
#513 were used to amplify cspB lacking the stop codon from from C. perfringens ATCC 
13124 genomic DNA (a kind gift of Jimmy Ballard). The PCR product was digested with 
NdeI and XhoI, ligated to pET22b, and transformed into DH5α. The resulting pET22b-
cspB perfringens plasmid was transformed into BL21(DE3). To construct a strain 
expressing the mature form of CspB perfringens carrying a C-terminal His6-tag, primers 
#670 and #671 were used to amplify cspB missing the N-terminal 96 aa and carrying a C-
terminal His6-tag. The PCR product was digested with NdeI and XhoI and ligated to 
pRSFduet1 digested with the same enzymes. The resulting pRSFduet1-cspB ∆96 (C. 
perfringens) plasmid was transformed into BL21(DE3). This plasmid was also used to 
clone a series of transcomplementation constructs. Specifically, primers #668 and #701 
were used to amplify the prodomain region of CspB perfringens (1-96 aa); primers #668 
and #771 were used to amplify aa 1-92 of the CspB perfringens prodomain region; 
primers #668 and #772 were used to amplify aa 1-93 of the CspB perfringens prodomain 
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region;  primers #703 and #704 were used to amplify the prodomain region of CspC 
perfringens; and primers #457 and #702   were used to amplify the prodomain region of 
CspBA difficile (1-66 aa). A stop codon was added to the 3’ primer of all these prodomain 
constructs. The resulting PCR products were digested with NcoI and SalI and ligated to 
pRSFduet1-cspB ∆96 plasmid that had been digested with the same enzymes. The 
resulting plasmid constructs were transformed into BL21(DE3). 
To construct a strain expressing full-length CspB perfringens carrying a C-
terminal His6-tag, primers #512 and #671 were used to amplify cspB carrying a C-terminal 
His6-tag. The PCR product was digested with NdeI and XhoI and ligated to pRSFduet1 
digested with the same enzymes. The resulting pRSFduet1-cspB (C. perfringens) plasmid 
was transformed into BL21(DE3). This plasmid was also used to introduce a series of 
point mutations using site-directed mutagenesis. Primer pair #516 and 517 was used to 
introduce the catalytic S494A mutation; primer pair #868 and 869 were used to introduce 
the S96R prodomain mutation; primer pair #709 and 710 was used to introduce the K91D 
prodomain mutation; primer pair #818 and 819 and primer pair #765 and 766 were used to 
introduce the R231Q and R231E salt bridge mutations, respectively; primer pairs #820 
and 821 and #952 and 953 were used to introduce the E35R and E35Q salt bridge 
mutations, respectively; and primer pair #822 and 823 was used to introduce the E59A salt 
bridge mutation. To construct the E35R-R231E salt bridge swap construct, plasmid 
pRSFduet1-cspB R231E was used as the template in a site-directed mutagenesis PCR 
reaction using primer pair #820 and 821. The resulting plasmids were transformed into 
BL21(DE3). 
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PCR SOE was used to construct the YTS_AAA cleavage site mutation construct 
by using primer pair #512 and 741 to amplify the 5’ fragment and primer pair #740 and 
671 to amplify the 3’ fragment. The resulting PCR products were purified and used in a 
second PCR reaction containing flanking primer pair #512 and 671. The PCR SOE 
product was digested with NdeI and XhoI and ligated to pRSFduet1 digested with the 
same enzymes to produce the pRSFduet1-cspB YTS/AAA plasmid. A similar strategy was 
used to delete the P3-P1 residues of CspB perfringens to produce plasmid pRSFduet1-
cspB ∆YTS, with the exception that the SOE primers were #774 and #773. To delete the 
jellyroll domain of CspB perfringens, the same PCR SOE strategy was used except that 
the SOE primers were #718 and #717. The resulting plasmids were transformed into 
BL21(DE3). 
To construct an expression construct producing the isolated jellyroll domain, 
primer pair #753 and 754 were used to amplify the region corresponding to aa 293-424 of 
cspB perfringens. The resulting PCR product was digested with NdeI and XhoI and 
ligated into pET22b digested with the same enzymes to produce plasmid pET22b-cspB 
jelly (293-424). This construct was transformed into BL21(DE3). 
 
2.3.3. Protein Sequencing.  
The N-termini of CspB variants were mapped using Edman sequencing and 
performed by the Protein and Nucleic Acid Facility at Stanford University. Briefly, 10 µg 
of each CspB variant was resolved by SDS-PAGE and transferred to a PVDF membrane. 
The membrane was stained with Ponceau S (0.1% w/v, 5% acetic acid), and CspB was 
excised from the membrane and sequenced using Edman degradation. 
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2.3.4. Protein Purification.  
For purification of His6-tagged proteins, overnight cultures of the appropriate 
BL21(DE3) strain were diluted 1:500 in 2L 2YT (5 g NaCl, 10 g yeast extract, 15 g 
tryptone/L) media and grown shaking (225 rpm) at 37ºC.  When an OD600 of 0.6-0.9 was 
reached, IPTG was added to 250 µM, and cultures were grown for 12-16 hr at 19ºC.  
Cultures were pelleted, resuspended in 25 mL lysis buffer [500 mM NaCl, 50 mM Tris-
HCl, pH 7.5, 15 mM imidazole, 10% v/v glycerol] and flash frozen in liquid nitrogen.  
Lysates were thawed, then lysed by sonication and cleared by centrifugation at 15,000 x g 
for 30 minutes.  His6-tagged proteins were affinity purified by incubating the lysates in 
batch with 1.0 mL Ni-NTA Agarose beads (Qiagen) with shaking for 3 hr at 4ºC.  The 
binding reaction was pelleted at 1,500 x g, the supernatant was set aside, and the pelleted 
Ni-NTA agarose beads were washed 3 x with lysis buffer.  His6-tagged proteins were 
eluted from the beads by the addition of 350 µL high imidazole elution buffer [500 mM 
NaCl, 50 mM Tris-HCl, pH 7.5, 175 mM imidazole, 10% v/v glycerol].  The elution was 
repeated four times; the eluate was pooled, buffer exchanged in gel filtration buffer [200 
mM NaCl, 10 mM Tris pH 7.5, 5% v/v glycerol), and concentrated to 750 µL. The 
concentrated prep was pelleted at 13,000 x g for 10 min at 4˚C prior to loading on a 
Superdex 200 10/30 column (GE Healthcare).  
For crystallization studies, C-terminally His6-tagged CspB perfringens was affinity 
purified as described above then gel purified using a HiPrep S200 16/60 Sephacryl column 
(GE Healthcare); the gel filtration buffer was 150 mM NaCl, 10 mM Tris pH 7.5. The 
purified protein was concentrated to 10 mg/mL. A single peak was observed by gel 
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filtration, with the elution volume indicating that CspB likely exists as a monomer based 
on a calibration curve determined using gel filtration standards (data not shown). 
Consistent with this observation, the elution volume was independent of protein 
concentration. Protein purity was analyzed by SDS-PAGE followed by Coomassie 
staining (GelCode Blue, Pierce).  
To prepare seleno-methionine (SeMet) substituted CspB for crystallization studies, 
an overnight culture of B384(DE3) harboring pET22b-CspB perfringens was grown in 60 
mL minimal media [7.5 mM (NH4)2SO4, 30 mM KH2PO4, 60 mM K2HPO4,  800 mg/L 19 
amino acids excluding methionine, 5% w/v glucose, 1 mM MgSO4, 4 mg/L thiamine, 4 
mg/L D-biotin] supplemented with 5% LB media.  The overnight culture was diluted 
1:100 in 6 L minimal media supplemented with 100 mg/L SeMet (Sigma) and grown for 6 
hr until an OD600 of 0.6 was reached.  Cultures were induced with 250 µM IPTG and 
grown at 30ºC for an additional 3 hr. SeMet-substituted CspB was purified using a similar 
protocol to native CspB with the exception that SeMet-substituted CspB was first purified 
on a 5 mL HiTrap Q anion-exchange column before gel filtration. Affinity-tagged SeMet-
substituted CspB was buffer-exchanged into 10 mM Tris-HCl pH 7.5 (buffer A) using an 
Amicon Ultra-10 (Millipore) before loading it onto the HiTrapQ column; it was eluted 
over 20 column volumes using 0.75 M NaCl, 10 mM Tris-HCl pH 7.5 as buffer B. 
Fractions containing SeMet-labeled CspB perfringens were pooled, buffer-exchanged into 
the 150 mM NaCl, 10 mM Tris-HCl pH 7.5 gel filtration buffer, and purified by gel 
filtration. 
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2.4. Results 
2.4.1. CspBA is processed during incorporation into C. difficile spores 
The cspBA fusion gene is encoded in the genomes of only five clostridial species 
(Figure S2). C. difficile is unique among these species in that the CspA portion of CspBA 
(CD2247) lacks an intact catalytic triad (Figures 1A and S2). In order to determine 
whether CspBA is produced as a fusion protein, we raised antibodies against the CspB 
portion of CspBA and analyzed CspB production in both sporulating cells and purified 
spores by Western blotting. As a control, we constructed a targeted gene disruption [108] 
of the cspBA-cspC (cd2247-cd2246) operon (Figure S1). In sporulating C. difficile cells, 
the anti-CspB antibody detected two polypeptides of ~130 kDa and ~55 kDa (Figure 1B). 
The former corresponds to the predicted MW of CspBA of 125 kDa, while the latter 
corresponds to the size of Csp proteases detected in C. perfringens spores (~60 kDa) [91]. 
Notably, the ~55 kDa protein was enriched in purified spores, suggesting that interdomain 
cleavage of CspBA occurs during spore formation and that CspB may be preferentially 
incorporated into the developing spore. Although the mutant strains exhibited similar 
levels of sporulation (Figure 1C), CspB levels in sleC– mutants spores were consistently 
~3-fold lower than in wildtype spores (Figure 1B). Nevertheless, these results indicate that 
CspBA is processed to CspB during C. difficile spore assembly. 
While the cspBAC locus was previously identified by transposon mutagenesis as 
being essential for C. difficile spore germination [92], the effect of CspBA on SleC cortex 
hydrolase processing was not tested. To determine whether loss of CspBA prevents SleC 
processing, we analyzed SleC cleavage in response to a bile salt germinant [55] by 
Western blotting. As predicted, disruption of cspBAC in C. difficile prevented SleC 
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cleavage during germination (Figure 1B), and this defect could be complemented by 
ectopic expression of the cspBAC locus from a multicopy plasmid [112] (Figure S1). 
Thus, the cspBAC locus appears to regulate SleC activity in a manner similar to C. 
perfringens [65, 70, 89, 91]. 
 
2.4.2. CspB undergoes autoprocessing in a position-dependent manner 
In order to gain insight into the mechanism by which CspBA activates SleC during 
germination, we conducted structure-function analyses of the CspB domain of CspBA, 
since CspB is the only Csp protease encoded by C. difficile with an intact catalytic triad 
(Figure 1A). Based on its homology to subtilases [91] (Figure S3), we hypothesized that 
CspB is synthesized as a pro-enzyme that undergoes autoprocessing. To test this 
hypothesis, we recombinantly produced wildtype CspB difficile (residues 1-548 of 
CspBA) and CspB perfringens, along with mutants with the catalytic serine inactivated, 
and compared their apparent MW by SDS-PAGE. Whereas mutation of the catalytic 
serine caused both CspB difficile and CspB perfringens to run at their expected MWs of 
~60 kDa, the wildtype CspB proteins migrated with MWs of ~55 kDa (Figure 2A). Thus, 
Csps autocatalytically remove their prodomain in a manner similar to other subtilases.  
Using Edman degradation, we mapped the autoprocessing site of CspB difficile (1-
548 aa) to Gln66 (data not shown). Alignment of this autocleavage site with previously 
mapped processing sites for CspA, CspB, and CspC of C. perfringens [91] revealed that 
Csps cleave at a similar position relative to their mature domains (Figure 2B and S4). 
Given the limited conservation in amino acid sequence around the Csp autoprocessing 
sites (Figures 2B and S4), we tested whether CspB recognizes specific amino acid 
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residues upstream of the cleavage site. Mutation of the CspB perfringens P1 serine to a 
bulky, charged Arg did not affect autoprocessing (P1 refers to the residue N-terminal to 
the scissile bond based on the Schecter and Berger convention [113], Figure 2A); 
similarly, mutation of the P3-P1 residues to alanine did not affect CspB perfringens and 
CspB difficile autoprocessing (Figure 2) or the position of cleavage (data not shown). In 
contrast, deletion of the P3-P1 residues (∆YTS) of CspB perfringens markedly reduced 
prodomain cleavage (Figure 2A), suggesting that the length of the prodomain affects 
substrate recognition or binding. 
 
2.4.3. Overall structure of CspB 
While these findings highlighted similarities between Csps and other subtilases, all 
CspB proteins capable of undergoing autoprocessing unexpectedly remained in complex 
with their prodomain following multiple rounds of purification (Figure 2A). In contrast, 
all previously characterized prokaryotic subtilases degrade their prodomain shortly after 
autoprocessing [96]. To gain insight into the interaction between the prodomain and 
subtilase domain, we determined the crystal structure of the CspB homolog from C. 
perfringens. CspB contains a subtilase domain that is similar to other subtilisin-like 
proteases [96], with the active site tucked within a conserved fold comprised of a six-
stranded antiparallel β-sheet that is sandwiched between four conserved α-helices (Figure 
3A). The catalytic triad of the active site of CspB superimposes directly with other active 
subtilisin-like proteases (Figure 3C), with an RMSD over the Cα atoms of only 0.11 Å 
between the catalytic triads of CspB and Tk-SP, the most structurally related enzyme from 
Thermococcus kodakaraensis as determined by the Dali server [114, 115].  
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In contrast with all previously solved prokaryotic subtilase structures, the 
autoprocessed prodomain stays bound to the wildtype, mature enzyme in our CspB 
structure. Notably, structures of prokaryotic subtilases in complex with their prodomain 
exist only for active site mutants [116-120]. The prodomain of CspB exhibits a similar 
structural organization to these subtilases, consisting of a 4-stranded antiparallel β-sheet 
and 3 α-helices (Figure 3A), with an additional β-strand extending into the catalytic cleft. 
The C-terminus of the CspB prodomain also extends directly into the oxyanion hole, with 
19 hydrogen bonds stabilizing the intimate interaction between the C-terminal P6-P1 
residues of the prodomain and the catalytic cleft (Figure S5 and Table S1). The 
prodomain-subtilase domain interface buries 1,472 Å2 of accessible surface area (Figure 
3C). 
A second major feature that distinguishes the structure of CspB from other 
subtilases is the interruption of the protease domain by an ~130 aa insertion (Figure S3). 
This insertion assumes a β-barrel jellyroll fold, consisting of nine antiparallel β-strands 
that pack in a small hydrophobic core. The jellyroll domain interacts with both the 
prodomain and subtilase domain (Figure 3 and S5, Table S1). Although a similar jellyroll 
fold is present in the archaeal subtilisin Tk-SP [114] (Figures 3D and 4A, RMSD of 2.1 Å 
over 81 Cα atoms), the Tk-SP jellyroll domain is a C-terminal extension that interacts 
exclusively with the subtilase domain (Figure 3D). Nevertheless, both Tk-SP and CspB 
hold their jellyroll domains tightly in place with 22 and 19 bonds (primarily hydrogen 
bonds, Table S1), with a buried surface area between the jellyroll domain and subtilase 
domain of 1,115 Å2 and 1,018 Å2, respectively. 
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2.4.4. The jellyroll domain rigidifies CspB 
In Tk-SP, the jellyroll domain has been shown to stabilize enzyme activity at high 
temperatures (>90˚C) [114]. To test whether the jellyroll domain might similarly stabilize 
CspB, we compared the susceptibility of wildtype CspB and a mutant lacking the jellyroll 
domain (CspB ∆jelly) to limited proteolysis. In vitro structure-function analyses were 
done on CspB perfringens rather than C. difficile because the structure was solved for 
CspB perfringens. In the presence of increasing concentrations of chymotrypsin, wildtype 
CspB exhibited remarkable resistance to degradation even when chymotrypsin levels were 
approximately equimolar to CspB (0.5 mg/mL or 20 µM chymotrypsin, Figure 4B). While 
mutation of the catalytic serine had little effect on CspB degradation, deletion of the 
jellyroll domain sensitized the mutant to chymotrypsin digestion at 50 ng/mL (Figure 4B). 
Loss of the jellyroll domain also reduced the efficiency of CspB autoprocessing, since 
both uncleaved and mature CspB ∆jelly were observed following purification. In contrast, 
only uncleaved CspB ∆jelly was observed upon mutation of the catalytic serine (Figure 
4B). Taken together, these results implicate the jellyroll domain in (1) positioning the 
prodomain to undergo autocleavage and (2) markedly restraining the conformational 
flexibility of CspB. 
 
2.4.5. The prodomain functions as an intramolecular chaperone 
Having identified functions for the jellyroll domain, we next investigated the role 
of the prodomain in regulating CspB activity. For many subtilases, the prodomain acts as 
an intramolecular chaperone that catalyzes proper folding of the subtilase domain; once 
folding is complete, the mature enzyme autocatalytically separates the prodomain from its 
  41 
subtilase domain [95, 96]. In most subtilases, the prodomain acts as a temporary inhibitor 
until it is autoproteolytically removed [96, 121]. To determine the extent to which Csps 
follow this model of subtilase maturation, we examined the chaperone activity of the 
CspB prodomain. Similar to other subtilases, deletion of the prodomain dramatically 
reduced the solubility and yield of mature CspB, while co-expression of the prodomain in 
trans restored folding to the subtilase domain (Figure S6). The chaperone activity of the 
prodomain was highly specific for CspB perfringens, since co-expression of the 
prodomains of CspB difficile and CspC perfringens in trans only marginally restored 
folding to the subtilase domain (Figure S6).  
Indeed, the CspB subtilase domain recognizes its prodomain with an extensive 
network of interactions, consisting of 27 hydrogen bonds and three salt bridges (Figure S5 
and Table S1 in Text S1). The prodomain adopts a similar fold to the prodomains of 
related subtilisin-like proteases (Figure 5A), with the C-terminal region extending deep 
into the catalytic cleft (Figure 3A). The 94 Cα atoms of the prodomain align with an 
RMSD of 2.4 Å compared to the Tk-SP prodomain and 2.5 Å when compared to the 
mammalian proprotein convertase subtilisin kexin type 9 (PCSK9), respectively [43].  
We compared the CspB prodomain to the PCSK9 prodomain because PCSK9 is 
the only other example of a wild-type subtilase that remains bound to its prodomain [122-
124], whereas the prodomain of Tk-SP only stays bound if the catalytic serine of Tk-SP is 
mutated to cysteine [119, 120]. Since we did not observe any obvious structural 
differences to account for the difference in prodomain retention, we examined the free 
energy of dissociation of prodomains from their cognate subtilase domains using PDBe 
PISA, which is a computational server for examining interaction interfaces on proteins 
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[125]. This analysis revealed that CspB and PCSK9 have the highest energy barriers to 
prodomain dissociation relative to other subtilases bound to their cognate prodomain or 
inhibitor (∆G = -19.2 and -17.7 kcal/mol, respectively, Figure 5B). Interestingly, while 
most of the interactions holding the prodomain to the subtilase domain are not sequence 
specific (Table S1), with 15 bonds directed at backbone atoms, there are a few salt bridges 
that mediate specific recognition of the prodomain (Figure 5C). These salt bridges occur 
between Glu35/Glu59 of the prodomain and Arg231 of the subtilase domain and between 
Lys91 of the prodomain and Asp257 of the subtilase domain (Figure 5C).  To determine 
the contribution of these salt bridges to CspB folding, we mutated each salt bridge residue 
and analyzed the effect on CspB solubility. Mutations of Glu35 to glutamine and Glu59 to 
alanine slightly reduced yields relative to wildtype, whereas mutation of Arg231 to 
glutamine strongly decreased recovery of CspB (Figure 5D), presumably because it 
disrupts both potential salt bridge interactions. Flipping the charges on Glu35 and Arg231 
(E35R or R231E, respectively) also significantly reduced CspB yields, while swapping the 
Glu35-Arg231 salt bridge (E35R-R231E) failed to rescue CspB solubility. In contrast, 
flipping the charge on Lys91 to aspartate (K91D), which forms a salt bridge with subtilase 
domain residue Asp257, had little effect on K91D solubility relative to wildtype CspB 
(Figure 5C and 5D, Table S1). Taken together, these results highlight the importance of 
the Glu35-Arg231 and Glu59-Arg231 prodomain-subtilase domain salt bridges in 
promoting subtilase domain folding.  
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2.4.6. The prodomain C-terminus sterically occludes a catalytically competent active 
site 
Having demonstrated the intramolecular chaperone activity of the prodomain, we 
next tested whether the prodomain functions as an inhibitor similar to other subtilases. 
Consistent with this hypothesis, the C-terminal P3-P1 residues of the prodomain bind the 
catalytic site in a manner analogous to an inhibitory peptide, fitting snugly within the 
catalytic cleft and presumably occluding access to the active site residues (Figure 6A). 
The S1 and S2 binding pockets perfectly accommodate the P1 serine and P2 threonine (P1 
refers to the residue N-terminal to the cleavage site; S1 refers to the P1 substrate binding 
pocket). The bulky P3 tyrosine residue is wedged between Arg222 and Ser254 of the 
subtilase (Figure S5 and Table S1). The C-terminal P1-P3 prodomain residues form a total 
of 13 bonds to the S1-S3 regions of the subtilase domain. The P1 Ser96 forms seven 
hydrogen bonds with NE2 of catalytic His183, Ser252, Asn287, Thr493 and catalytic 
Ser494; P2 Thr95 forms four hydrogen bonds to different atoms of Arg222; and P3 Tyr94 
forms hydrogen bonds to both the backbone amide and carbonyl of Ser254. 
To test whether these residues block substrate access to the CspB active site, we 
used a small activity-based probe (FP-Rh, Figure 6B) to detect CspB catalytic activity. 
The fluorophosphonate electrophilic group of the probe reacts exclusively with 
catalytically competent serine hydrolases such as the subtilisins, which are a subfamily of 
the subtilases [126]. Nucleophilic attack by the catalytic serine results in the probe 
becoming covalently bound to the catalytic serine, while the rhodamine tag allows for 
detection of the covalently labeled enzyme by fluorescent gel scanning. Incubation of 
either wildtype or catalytically inactive S461A CspB with FP-Rh failed to produce 
detectable fluorescence, implying that the active site is inaccessible in the wildtype 
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enzyme (Figure 6C). In contrast, mutation of the P3-P1 residues (YTS/AAA) produced a 
CspB variant that could be labeled on its catalytic serine, suggesting that the C-terminal 
prodomain residues act as gatekeepers to a catalytically competent active site. 
Accordingly, truncation of the C-terminal gatekeeper of the prodomain expressed in trans 
of residues YTS (P3-P1) or LYTS (P4-P1) permitted labeling of the CspB active site, 
whereas the full-length prodomain expressed in trans prevented labeling (Figure 6C). 
Taken together, these results indicate that the C-terminal YTS prodomain residues inhibit 
CspB activity. 
 
2.4.7. The CspB jellyroll domain stabilizes CspBA 
Having identified key structural features of CspB perfringens in vitro, we next 
tested their functional significance in regulating CspBA activity in C. difficile. To this end, 
we cloned cspBAC complementation constructs in which the jellyroll domain was deleted 
(∆jelly, Figure 7A) or the active site serine was mutated (S461A). The cspBAC constructs 
were expressed from their native cspBA promoter on a multicopy plasmid (pMTL83151) 
[112]. Deletion of the jellyroll domain appeared to destabilize CspBA, since CspBA ∆jelly 
levels were markedly reduced relative to wildtype and the cspBAC complementation strain 
and degradation products were apparent (Figure 7B). In contrast, mutation of the catalytic 
serine (S461A) did not affect CspBA levels relative to the cspBAC complementation 
strain, although CspBA S461A failed to undergo autoprocessing (Figure 7B). In purified 
spores, the predominant form of CspB was autoprocessed (m-CspB) in wildtype and 
cspBAC-complemented spores, whereas the predominant form of CspB in S461A spores 
was not autoprocessed (Figure 7C). Given that CspBA S461A was still processed at the 
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CspB-CspA junction, an as-yet-unidentified protease apparently separates CspB from 
CspA.  
To determine the role of CspBA autoprocessing in C. difficile spore germination, 
we examined the ability of S461A mutant spores to germinate in response to bile salts. 
Relative to wildtype and cspBAC-complemented spores, S461A mutant spores exhibited 
an ~20-fold defect in germination and SleC cleavage (Figure 7C), while loss of the 
jellyroll domain (∆jelly) reduced spore germination by ~70-fold  (Figure 7C). 
Nevertheless, loss of CspBA and CspC production in the cspBAC– mutant produced a 
more severe phenotype than loss of the catalytic activity (S461A) or jellyroll domain 
(∆jelly) of CspBA. Taken together, these results indicate that CspB catalytic activity and 
its jellyroll domain are required for efficient C. difficile spore germination.  
 
2.4.8. The protease activity of CspBA is required for germination downstream of 
autoprocessing 
The observation that ~5% of pro-SleC undergoes cleavage during germination of 
S461A mutant spores (Figure 7C) raised the question as to how SleC was being activated 
in the absence of CspB protease activity. One possibility is that a redundant protease 
cleaves SleC during germination of S461A mutant spores. Another possibility is that CspB 
activates a second protease that directly cleaves SleC. While this latter model is more 
complicated, it reflects how the subtilisin-like proprotein convertase PCSK9 indirectly 
regulates low-density lipoprotein receptor (LDLR) levels. Rather than enzymatically 
degrading LDLR, PCSK9 binds and targets LDLR to the lysosome [121, 127]. However, 
in order to bind LDLR, PCSK9 must undergo autoprocessing to form a non-covalent 
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complex with its prodomain; only after autoprocessing can PCSK9 recognize LDLR [121, 
127]. As a result, PCSK9 is the only other wildtype subtilisin-like protease that retains its 
prodomain in its crystal structure following autoprocessing [122-124]. 
If CspB activity is regulated similarly to PCSK9, CspB protease activity should be 
dispensable once autoprocessing has occurred. To test this hypothesis, we co-expressed 
the CspBA prodomain with a CspBA variant lacking its prodomain such that the CspBA 
produced is identical to wildtype CspBA after autoprocessing (Q66, Figure 8A). The 
prodomain was also co-expressed with a catalytically inactive CspBA variant lacking its 
prodomain (Q66/S461A, Figure 8A). As predicted, Q66 and Q66/S461A 
transcomplementation mutants produced CspBA variants that were indistinguishable in 
size from wildtype in sporulating cells (Figure 8B) and purified spores (Figure 8C), 
although more CspBA fusion protein was observed in the transcomplementation mutant 
spores relative to wild type (Figure 8C). Nevertheless, Q66/S461A mutant spores 
exhibited a 10-fold defect in both germination and SleC cleavage relative to wildtype and 
Q66 mutant spores. This result indicates that the catalytic activity of CspBA is required 
for efficient SleC cleavage downstream of CspBA autoprocessing. 
 
2.5. Discussion 
Spore germination is essential for Clostridium sp. pathogens such as C. perfringens 
and C. difficile to initiate infection [56, 85]. A critical step during germination is the 
degradation of the thick, protective cortex layer surrounding the spore core by cortex 
hydrolases [56, 86, 87]. However, despite their functional importance, little is known 
about the molecular mechanisms that control cortex hydrolase activity. In this study, we 
  47 
provide the first molecular insight into cortex hydrolase regulation by solving the structure 
of CspB, a protease required for cortex hydrolase activation. Combined with our 
functional analyses of CspB in vitro and in vivo, the structure reveals that Csps are 
subtilisin-like proteases with two distinctive functional features: a central jellyroll domain 
and a retained prodomain. 
The central β-barrel jellyroll domain of CspB interrupts the subtilase domain and 
wedges itself tightly between the subtilase domain and prodomain in three-dimensional 
space (Figure 3C). This unique position is likely critical for CspB function, since the 
jellyroll domain markedly restrains the conformational mobility of CspB through 
extensive and specific interactions at the subtilase-jellyroll domain interface (Figure 4B 
and S5). The rigidity conferred by the jellyroll domain presumably helps CspB survive the 
environmental extremes that spores can encounter, such as freeze-thaw cycles and boiling 
temperatures [28]. The jellyroll domain also facilitates CspB autoprocessing in vitro 
(Figure 4B), indicative of a role in helping CspB adopt the correct subtilase fold. 
Consistent with this proposal, deletion of the jellyroll domain in C. difficile markedly 
reduced CspBA levels relative to wild type (Figure 7B).  
In these respects, the jellyroll domain is more functionally analogous to the β-
barrel P-domains of kexin-like subtilisins than to the jellyroll domain of prokaryotic Tk-
SP subtilisin. Like the CspB jellyroll domain, the P-domain of kexin-like proteases, such 
as the mammalian enzyme furin, is important for autoprocessing, folding, stability, and 
activity of the subtilase domain [96, 121, 128-130]. In contrast, the jellyroll domain of Tk-
SP is dispensable for autoprocessing, protein folding and activity in vitro, despite being 
important for Tk-SP thermostability [114].  
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The retention of the CspB prodomain is another unique feature identified by our 
study. Unlike the majority of subtilisin-like proteases, the prodomain stays bound to the 
wildtype subtilase domain via a network of interactions that result in tighter prodomain 
binding relative to other subtilases (Figure 5B and S5). Prodomain binding to its cognate 
protease appears highly specific, since prodomain swapping does not result in efficient 
folding of CspB (Figure S6). This conclusion is consistent with the limited sequence 
conservation of prodomains across Csps (Figure S3); indeed, even the salt bridges critical 
for prodomain chaperone activity (Figure 5D) are not conserved. Despite the low level of 
sequence conservation, the position of prodomain autoprocessing is highly conserved 
(Figure 2B), and a small internal deletion of the prodomain disrupts autocleavage even 
though diverse residues are tolerated at the P1 position (Figure 2A).  
Mechanistically, Csps exhibit less specificity in P1 substrate recognition than most 
subtilases [131-135]. Nevertheless, while residues around the prodomain cleavage site do 
not affect autocleavage efficiency, they do control active site accessibility after 
autoprocessing, excluding even a small, highly reactive, serine protease probe in vitro 
(Figure 6C). Taken together, Csps appear more functionally similar to the site-specific 
kexin-like protease subfamily than to the highly processive subtilisin subfamily [93, 96]. 
Similar to kexin-like proteases, Csps cleave their putative substrate, SleC, at a single site 
during germination [65] (Figure 1B) and remain more closely associated with their 
prodomain following autoprocessing [96, 121]. By contrast, subtilisin subfamily members 
such as Tk-SP function as major degradative enzymes that rapidly degrade their 
prodomain following autoprocessing [96]. 
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While these observations provide new insight into the structure and function of 
Csp proteases, they raise a number of questions for future study. Does the prodomain 
remain associated with autoprocessed CspB in dormant spores as it does in vitro? If the 
prodomain stays bound to mature CspB in dormant spores, what happens to the prodomain 
during germination? Given that chymotrypsin cannot access numerous prodomain 
cleavage sites during extended incubation in vitro (Figure 4), a significant change in CspB 
conformational mobility would appear to be required for the prodomain to be degraded 
and its putative substrate SleC to gain access to the CspB substrate binding pocket.   
Another question raised by our study is the role of CspC in regulating germination 
in C. difficile. Given that ∆jelly, S461A, and Q66/S461A mutant spores exhibit 
germination defects that are >100-fold less severe than cspBAC– spores and that a major 
difference between these mutant spores is the absence of CspC in cspBAC– mutant spores 
(Figures 7 and 8), catalytically inactive CspC (Figure 1A) may play a role in SleC 
activation. Recent data suggests that CspC helps transduce the germination signal to CspB 
(J. Sorg, personal communication). In addition, it is unclear what fraction of pro-SleC 
must be proteolytically activated to induce successful spore germination. Approximately 
5% of spores of the CspBA catalytic mutant S461A successfully germinate, which 
correlates with a small fraction of pro-SleC undergoing processing in the mutant strain 
(Figure 8). This result suggests that only a small fraction of SleC must be proteolytically 
activated in order to mediate spore germination in some cells; alternatively, a small 
fraction of S461A spores could efficiently cleave pro-SleC and thus germinate 
successfully.  
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While further experimentation is needed, the work presented here provides the first 
structure-function analyses of Csp proteases in vitro and in vivo and lays the groundwork 
for mechanistically addressing how the germination pathway senses and integrates the 
germination signal. Furthermore, this study may provide the structural basis for designing 
therapeutics that either block prodomain and/or jellyroll domain binding to the CspBA 
subtilase domain during spore formation or prematurely activate CspBA to induce cortex 
hydrolysis. These CspBA agonists or antagonists could prevent C. difficile transmission 
and disease recurrence. 
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Figure 2.7.1. The CspBA fusion protein undergoes processing during sporulation. 
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 (a) Schematic of Csps and SleC in C. perfringens and C. difficile. Intact catalytic 
residues are black, while catalytic mutations are grey. The prodomain of C. perfringens 
Csps are shown in light grey, with their lengths indicated. The predicted prodomain of 
CspBA is also indicated.  SleC is outlined in black, with the prepeptide (Pre), propeptide 
(Pro), and Csp cleavage site indicated for C. perfringens SleC [66, 90] (b) Western blot 
analysis of sporulating C. difficile and purified spores. Purified spores of the indicated 
strain were either untreated (–) or exposed to 0.2% w/v sodium taurocholate [55] (+, 
germinant) for 15 min at 37˚C and analyzed by Western blotting and for germination 
efficiency via colony forming unit (cfu) determination. The processing products of CspB 
and SleC are indicated. CD1433 was previously shown to be a component of C. difficile 
spores and is used as a loading control [99]; the anti-CD1433 antiserum primarily 
recognizes the chitinase domain of CD1433. CspB levels were 3.5-fold lower in sleC– 
spores relative to wildtype spores, despite containing similar amounts of CD1433. (c) 
Phase-contrast microscopy of sporulating C. difficile strains used in (b) showing 
equivalent levels of sporulation as measured by particle counting. The white triangles 
indicate mature phase-bright spores that have been released from the mother cell; the 
black triangles highlight immature forespores in the mother cell. 
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Figure 2.7.2. CspB undergoes autoprocessing in a position-dependent manner 
  
(a) Coomassie staining of recombinant C. perfringens and C. difficile CspB 
variants. 7.5 µg of each purified CspB variant was resolved by SDS-PAGE on a 4-12% 
Bis-Tris gel and visualized by Coomassie staining. The P3-P1 residues of the prodomain 
were mutated to Ala for the YTS/AAA and QTQ/AAA mutants, while the P3-P1 residues 
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were deleted from CspB perfringens in the ∆YTS mutant. The products resulting from 
autoprocessing are indicated. (b) Sequence alignment of Csp prodomain cleavage sites 
mapped by Edman sequencing; the Csp perfringens cleavage sites were mapped in a 
previous study [91]. Completely conserved identical residues are blocked in black with 
white text, conserved identical residues in grey with white text, and conserved similar 
residues in light grey. 
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Figure 2.7.3. Overall structure of CspB perfringens 
 
 (a) Ribbon representation showing subtilase domain in purple, jellyroll domain in 
green, and prodomain in teal extending into the active site. Catalytic residues are shown as 
stick models with yellow carbons. (b) Close-up view of catalytic site. An overlay of CspB 
(purple) and Tk-SP (grey). The three catalytic residues are shown. Tk-SP and CspB 
catalytic residues are labeled in black and purple, respectively. (c) Space-filling model of 
CspB with same orientation and color scheme as (a). (d) Overlay of CspB (colors, same as 
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(a)) and Tk-SP (shown in grey), showing similar overall structures with the exception of 
the position of the jellyroll domain. The jellyroll domains of CspB and Tk-SP are shown 
in green and grey, respectively. Note that only the regions with conserved secondary 
structure in the prodomain and subtilase domain are shown. 
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Figure 2.7.4. The jellyroll domain conformationally rigidifies CspB perfringens 
 
 (a) Overlay of jellyroll domain of CspB perfringens (green) and Tk-SP (grey). (b) 
Limited proteolysis profile of CspB and its variants. 15 µM of CspB and its variants were 
incubated with increasing concentrations of chymotrypsin for 60 min at 37˚C. Reactions 
were resolved by SDS-PAGE and visualized by Coomassie staining. Schematic of CspB 
variants is shown below the Coomassie stained gel. “Pro” refers to the prodomain; black 
rectangle demarcates the jellyroll domain; thin white rectangle represents the jellyroll 
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deletion; and white star denotes the S494A mutation. m-CspB refers to mature CspB, 
which is produced after autoprocessing. 
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Figure 2.7.5. Dual salt bridges are required for prodomain intramolecular chaperone activity 
 
 (a) Overlay of prodomains from CspB perfringens (teal), Tk-SP (grey), and 
PCSK9 (pink). (b) PDBe PISA analyses of free energy of prodomain dissociation from 
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mature subtilase, with CspB in teal, PCSK9 in pink, and others in grey. (c) Close-up view 
of dual salt-bridge interaction at prodomain-subtilase interface. The C-terminus of the 
prodomain (C, teal) extends toward the substrate-binding pocket. Prodomain Glu35, 
Glu59 and Arg91 residues are shown in teal; subtilase domain Arg231 and D257 residues 
are shown in magenta. (d) Analysis of CspB prodomain mutant solubility using Western 
blotting and Coomassie staining. Cultures expressing cspB variants were induced with 
IPTG, and aliquots were removed 30 minutes later (“induced-IPTG” sample). Cells were 
lysed by sonication and centrifuged at high speed; the “cleared lysate” sample represents 
the soluble fraction. CspB variants were purified by affinity chromatography. Equivalent 
amounts of samples were resolved by SDS-PAGE and analyzed either by Western blotting 
using anti-CspB perfringens antisera or by Coomassie staining (bottom gel, affinity-
purified CspB). 
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Figure 2.7.6. C-terminal prodomain residues sterically occlude a catalytically competent active site 
(a) Close-up of interaction between prodomain C-terminus and substrate binding 
pocket. Subtilase, jellyroll and prodomains are shown in semi-transparent surface 
representation (purple, green, and teal, respectively). Residues 89-96 of prodomain are 
shown in yellow. (b) Structure of fluorophosphonate-rhodamine (FP-Rh) activity-based 
probe. Rhodamine dye is shown in red. (c) Schematic of CspB variants. “Pro” refers to the 
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prodomain; “+” reflects co-expression of the prodomain in trans, with the number 
reflecting the prodomain length. (d) Labeling of CspB variants by FP-Rh. CspB variants 
(10 µM) were incubated with 1 µM FP-Rh probe for 20 min at RT in triplicate. The 
labeling reactions were resolved by SDS-PAGE on a 15% gel and visualized by 
fluorescent scanning followed by Coomassie staining. A single representative replicate is 
shown. m-CspB refers to mature CspB lacking its prodomain.  
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Figure 2.7.7. The jellyroll domain and catalytic serine of CspBA are required for efficient germination 
 
 (a) Schematic of CspBA variants produced by cspBAC complementation 
constructs. “Pro” denotes the prodomain; black rectangle demarcates the jellyroll domain; 
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a thin white rectangle represents the jellyroll deletion; and white star indicates S461A 
mutation. (b) Western blot analyses of sporulating cells expressing cspBAC 
complementation constructs and (c) germinating spores expressing cspBAC 
complementation constructs. Purified spores of the indicated strain were either untreated 
(–) or exposed to 0.2% w/v sodium taurocholate (+, germinant) for 15 min at 37˚C and 
analyzed by Western blotting with the indicted antibodies. Germination efficiency was 
determined via colony forming unit (cfu) determination. Representative clones of each 
construct are shown, but more than two clones of each complementation construct were 
tested. m-CspBA reflects the mature form of CspBA following autoprocessing, and m-
CspB reflects the mature form of CspB following autoprocessing. The different mutant 
CspB variants are indicated.  
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Figure 2.7.8. CspBA activity downstream of autoprocessing is required for efficient SleC cleavage 
  
(a) Schematic of CspBA variants produced by cspBAC transcomplementation 
constructs. “Pro” denotes the prodomain; black rectangle demarcates the jellyroll domain; 
a thin white rectangle represents the jellyroll deletion; and white star indicates S461A 
mutation.  (b) Western blot analyses of sporulating cells expressing cspBAC 
transcomplementation constructs and (c) germinating spores expressing 
transcomplementation constructs. Purified spores of the indicated strain were either 
untreated (–) or exposed to 0.2% w/v sodium taurocholate (+, germinant) for 15 min at 
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37˚C and analyzed by Western blotting with the indicated antibody. Germination 
efficiency was determined via colony forming unit (cfu) determination. Representative 
clones of each construct are shown, but more than two clones of each complementation 
construct were tested. m-CspBA reflects the mature form of CspBA following 
autoprocessing, and m-CspB reflects the mature form of CspB following autoprocessing.  
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Figure 2.8.S1. Csp protease and SleC are required for spore germination in Clostridium sp. 
 
 (a) Schematic of sleC and csp genes in C. perfringens ATCC 13124 (gas gangrene 
isolate) [136], C. perfringens SM101 (food poisoning isolate) [136], and C. difficile 630. 
(b) Western blot analyses of sporulating cells and (c) germinating spores for cspBAC– 
complementation strains. Sodium taurocholate was used to stimulate germination for 20 
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min at 37˚C. The number of viable spores obtained upon plating on BHIS plates 
containing 0.2% w/v taurocholate is given as colony forming units (cfus). 
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Figure 2.8.S2. ClustalW sequence alignment of CspBA proteins 
 
Completely conserved identical residues are blocked in blue, conserved identical 
residues in green, and conserved similar residues in yellow. A red triangle indicates 
  70 
catalytic triad residues (also boxed in red). Note that the catalytic His of CspB difficile did 
not align with the other CspBA homologs, despite being conserved in position in 
alignments with isolated CspB proteins (Figures S3 and S4). Because of this discrepancy, 
the ClustalW alignment was altered to reflect the conservation of the catalytic His. 
CspBAs from C. butyricum (ZP_045298777), C. botulinum E3 (ZP_04529497), C. 
acetobutylicum (AE007820_5), Candidatus arhtomitus (EGX28514), and C. difficile 630 
(YP_001088762.1). We also note that C. tetani E88 encodes an N-terminally truncated 
CspBA homolog lacking the first Asp in the catalytic triad (AAO36820), but this was not 
included in the alignment. 
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Figure 2.8.S3. ClustalW sequence alignment of major classes of bacterial subtilisin-like proteases 
 
Completely conserved identical residues (blue), conserved identical residues 
(green), and conserved similar residues (yellow). A red triangle indicates catalytic triad 
residues (boxed in red). The central insertion corresponds to the jellyroll domain. Major 
intracellular serine proteases (ISP): B. subtilis str. 168 (NP_389202.1) and C. difficile 
(YP_001088508.1); extracellular serine proteases: AprE from B. amyloliquefaciens 
(YP_003919715.1) and subtilisin E from B. subtilis str. 168 (NP_388911.2); CspB: C. 
perfringens ATCC 13124 (YP_697251.1) and C. difficile 630, 1-548 aa 
(YP_001088762.1). 
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Figure 2.8.S4. ClustalW sequence alignment of diverse Csp proteases 
 
Completely conserved identical residues are blocked in blue, conserved identical 
residues in green, and conserved similar residues in yellow. A red triangle indicates 
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catalytic triad residues (also boxed in red). C. perfringens Csp prodomain cleavage sites 
are boxed in pink [91], while C. difficile CspB (1-548 aa) autoprocessing site is boxed in 
orange. α-helices and β-sheets in the CspB perfringens structure are indicated as a helix or 
a bracket above the sequence alignment, respectively. CspA Roseburia intestinalis 
(CBL08898), CspB Blautia hansenii (ZP_05853381), CspA Ruminococcus gnavus 
(ZP_02042115), CspA Coprococcus catus (CBK81001), CspC C. perfringens ATCC 
13124 (YP_697250), CspA C. perfringens ATCC 13124 (YP_697252), CspB C. 
perfringens ATCC 13124 (YP_697251), and CspB C. difficile 630, 1-548 aa 
(YP_001088762.1).  
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Figure 2.8.S5. Interaction interfaces within CspB perfringens 
 
The prodomain is shown in teal, the subtilase domain in purple, and the jellyroll 
domain in green. Each residue involved in a predicted hydrogen bond is shown as a stick 
model. Bonds predicted by PDBePISA [125] are shown as dashed grey lines.  All bonds 
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predicted by PISA have been drawn, but not all are visible. (a) Prodomain interaction with 
mature subtilase domain, with the prodomain C-terminus extending into the active site. 
The Glu35/Glu59/Arg231 salt bridge interactions (Fig. 5) are shown, and selected residues 
are labeled. (b) Jellyroll domain interaction with prodomain and subtilase domain.  
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Figure 2.8.S6. Csp prodomain transcomplementation 
 
 (a) Schematic of transcomplementation constructs. The source of the prodomain is 
indicated. (b) Western blot and Coomassie stain showing the purification of CspB 
transcomplementation mutants. Cultures expressing cspB variants were induced with 
IPTG, and aliquots were removed 30 minutes later (“induced” sample). During the 
purification process, a sample of the soluble fraction was removed (“cleared lysate” 
sample). These samples were resolved by SDS-PAGE and analyzed by Western blotting 
using an anti-CspB perfringens antibody. Following affinity purification of the His6-
tagged CspB variants, equivalent amounts of the “eluate” were loaded and analyzed by 
SDS-PAGE and Coomassie staining. 
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Figure 2.8.S7. Electron density maps of CspB perfringens 
 
 (a) Stereo view of bias-free, density-modified experimental map produced from 
SHELX/C/D/E [104] by SAD phasing using 12 selenium sites and prior to model building 
(map shown as dark blue mesh). The 1.6 Å map is contoured at 1 σ and shown over the C-
terminal residues (92-96) of the prodomain, the catalytic triad (Asp126, His183, and 
Ser494), and within a 3 Å radius of each atom. Prodomain residue carbons are shown in 
cyan and catalytic residue carbons in yellow. OXT indicates the prodomain C-terminus 
resulting from proteolytic cleavage. (b) 1.6 Å resolution anomalous electron density map 
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from SHELX/C/D/E showing selenium anomalous signal (orange mesh) in 
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2.9. Supporting Tables 
Table 2.9.S1. Interactions between prodomain and mature CspB and jellyroll domain and 
CspB subtilase domain as determined by PDBe PISA [125]. 
 
Table 2.9.S1.1.: Prodomain interaction interface with mature subtilase: hydrogen bonds and salt 
bridges. 
Hydrogen Bonds      
##  Prodomain  Dist. [Å]  Subtilase 
1 10 ASP OD2 2.76 362 TYR OH 
2 61 LEU O 2.77 269 TYR OH 
3 88 GLU OE1 2.73 265 LEU N 
4 88 GLU OE2 3.24 266 LEU N 
5 91 LYS O 2.84 226 SER N 
6 91 LYS N 2.88 226 SER OG 
7 91 LYS NZ 2.86 257 ASP O 
8 92 ILE O 2.9 255 THR OG1 
9 93 LEU O 2.87 224 ALA N 
10 93 LEU N 2.74 224 ALA O 
11 94 TYR O 2.97 254 SER N 
12 94 TYR N 2.88 254 SER O 
13 95 THR OG1 3.47 222 ARG NE 
14 95 THR O 2.82 222 ARG NH2 
15 95 THR N 3.01 222 ARG O 
16 95 THR OG1 3.7 222 ARG O 
17 96 SER O 3.24 183 HIS NE2 
18 96 SER OG 2.61 494 SER OG 
19 96 SER OXT 2.97 494 SER N 
20 96 SER OXT 2.82 287 ASN ND2 
21 96 SER OXT 3.38 493 THR N 
22 96 SER N 3.35 252 SER O 
23 96 SER OG 3.45 252 SER O 
 
Salt Bridges 
##  Prodomain  Dist. [Å]  Subtilase 
1 35 GLU OE1 3.51 231 ARG NH2 
2 35 GLU OE1 2.96 231 ARG NH1 
3 35 GLU OE2 2.97 231 ARG NH2 
4 35 GLU OE2 3.57 231 ARG NH1 
5 59 GLU OE1 2.83 231 ARG NH2 
6 59 GLU OE1 2.89 231 ARG NE 
7 59 GLU OE2 3.18 231 ARG NE 
8 91 LYS NZ 3.89 257 ASP OD2 
 
The distance between two atoms is shown for each bond; residue number, residue 3-letter 
code, and atom name specify each atom involved.  
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Table 2.9.S1.2.: Jellyroll domain interaction interface with mature subtilase: hydrogen bonds and salt 
bridges. 
Hydrogen Bonds      
 
## Jellyroll  Dist. [Å]  Subtilase 
1 291 SER N 3.26 288 GLU O 
2 291 SER N 3.49 290 ASN OD1 
3 291 SER OG 2.92 288 GLU OE2 
4 291 SER OG 3.21 287 ASN O 
5 293 HIS ND1 2.76 288 GLU OE1 
6 294 HIS ND1 3.18 425 SER O 
7 294 HIS O 2.82 425 SER N 
8 319 ASP OD2 3.28 258 GLY N 
9 362 TYR OH 2.76 10 ASP OD2 
10 370 ASP OD2 3.29 261 ASN ND2 
11 372 GLN OE1 3.55 261 ASN ND2 
12 406 ASP OD2 3.03 428 ASN ND2 
13 408 TRP NE1 2.89 428 ASN O 
14 409 LEU O 3.46 256 ASN ND2 
15 420 ARG NH2 2.84 290 ASN O 
 
Salt Bridges       
 
##  Jellyroll  Dist. [Å]  Subtilase 
1 406 ASP OD1 2.74 462 ARG NH1 
2 406 ASP OD1 3.46 462 ARG NH2 
3 406 ASP OD2 3.77 462 ARG NH1 
4 406 ASP OD2 3.01 462 ARG NH2 
 
Table 2.9.S1.3.: Jellyroll domain interaction interface with prodomain: hydrogen bonds. 
Hydrogen Bonds 
 ##  Jellyroll  Dist. [Å]  Prodomain 
1 362 TYR O 2.76 10 ASP OD2 
 
The distance between two atoms is shown for each bond; residue number, residue 3-letter 





  81 
 
Table 2.9.S2.: Strains and plasmids used in this study. 
 
Strain 
# C. difficile strain Relevant genotype or features 
Source/ 
reference 
11 JIR8094 Erm-sensitive derivative of 630 C. Ellermeier [97] 
13 630 Clinical isolate 630 T. Lawley [63] 
30 cspBAC– JIR8094 cspBAC::ermB This study 
47 sleC– JIR8094 sleC::ermB This study 
84 JIR8094/pMTL84151 JIR8094/pMTL84151 This study 
88 cspBAC–/pMTL84151 JIR8094 cspBAC::ermB/ pMTL84151 This study 
111 JIR8094/pMTL83151 JIR8094/ pMTL83151 This study 

























cspBAC Q66 This study 
 
E. coli strains with C. difficile constructs 
  





F– Φ80lacZΔM15 Δ(lacZYA–argF) U169 recA1 endA1 hsdR17 (rK–, 
mK+) phoA supE44 λ– thi-1 gyrA96 relA1 
D. Cameron 
 
BL21(DE3) F– ompT hsdSB(rB–, mB–) gal dcm (DE3) Novagen 
HB101 
F- mcrB mrr hsdS20(rB– mB–) recA13 leuB6 ara-13 proA2 lavYI 
galK2 xyl-6 mtl-1 rpsL20 C. Ellermeier 
531 pK424 in HB101 C. Ellermeier 
7 pET22b in DH5a D. Higgins 
269 pET28a in DH5a M. Bogyo 
548 pRSFDuet1 in DH5a Novagen 
556 pJS107 in DH5a J. Sorg 
686 pMTL83151 in HB101/pK424 This study 
655 pMTL83151 in DH5a This study 
455 pET28a-cspB(548aa) in BL21(DE3) This study 
471 pET28a-cspB(548aa)-S461A in BL21(DE3) This study  
493 pET28a-cspB(548aa)-QTQ/AAA in BL21(DE3) This study 
514 pET28a-cd1433 in BL21(DE3) This study 
516 pET22b-cspC (CD2246) in BL21(DE3) This study 
533 pET22b-sleC in BL21(DE3) This study 
604 pJS107 cspBA 81 in HB101/pK424 This study 
646 pJS107-sleC 128 in HB101/pK424 This study 
667 pMTL83151-cspBAC in HB101/pK424 This study 
799 pMTL83151-cspBAC S461A in HB101/pK424 This study  
800 pMTL83151-cspBAC ∆jelly in HB101/pK424 This study  
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891 pMTL84151-cspBAC Q66 in HB101/pK424 This study  
892 pMTL84151-cspBAC Q66/S461A in HB101/pK424 This study 
 
E. coli strains with C. perfringens constructs 
  
Strain #  Relevant genotype or features Source or reference 
506 pET22b-cspB in BL21(DE3) This study 
673 pRSFduet1-cspB∆96 in DH5a This study 
674 pRSFduet1-cspB∆96 in BL21(DE3) This study 
711 pRSFduet1-cspB in BL21(DE3) This study 
712 pRSFduet1-cspB(1-96)/cspB∆96 in BL21(DE3) This study 
713 pRSFduet1-cspBA difficile (1-66)/cspB∆96 in BL21(DE3) This study 
714 pRSFduet1-cspC perfringens (1-78)/cspB∆96 in BL21(DE3) This study 
742 pRSFduet1-cspB ∆jelly in BL21(DE3) This study  
744 pRSFduet1-cspB ∆jelly/S461A in BL21(DE3) This study 
745 pRSFduet1-cspB K91D in BL21(DE3) This study  
747 pRSFduet1-cspB S494A in BL21(DE3) This study  
753 pRSFduet1-cspB YTS/AAA in BL21(DE3) This study  
786 pET22b-cspB jelly (293-424 aa) in BL21(DE3) This study 
788 pRSFduet1-cspB(1-92)/cspB∆96 in BL21(DE3) This study 
789 pRSFduet1-cspB(1-93)/cspB∆96 in BL21(DE3) This study 
791 pRSFduet1-cspB R231E in BL21(DE3) This study  
792 pRSFduet1-cspB ∆YTS in BL21(DE3) This study  
793 pRSFduet1-cspB R231Q in BL21(DE3) This study  
820 pRSFduet1-cspB E35R in BL21(DE3) This study  
821 pRSFduet1-cspB E59A in BL21(DE3) This study  
822 pRSFduet1-cspB E35R-R231E in BL21(DE3) This study  
823 pRSFduet1-cspB S96R in BL21(DE3) This study  
 
Plasmids Relevant features Source or reference 
pET22b bla Novagen 
pET28a kan Novagen 
pRSFduet1 kan Novagen 
pK424 Tra Mob+; bla, tet C. Ellermeier 
pJS107 
C. difficile Targetron construct based on pJIR750ai (group II 
intron ermB::RAM, ltrA); catP J. Sorg 
pCE245 
C. difficile Targetron construct based on pJIR750ai (group II 
intron ermB::RAM, ltrA); catP C. Ellermeier 
pMTL83151 pCB102, Tra+; catP N. Minton [110] 
pMTL84151 pCD6, Tra+; catP N. Minton [110] 
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Table 2.9.S2.: Primers used in this study. 
 
# Name Sequence 
457 5' NcoI cspBA start 
ATACCATGGCTATTATAATAAATTATGAATTAATTGT
A 
459 3' XhoI cspBA 548 aa GCACTCGAGTGACTTATTAATACTTCTATATCC 
461 5' NdeI sleC AGCCATATGCAAGATGGTTTCTTAACAGTAAGC 
463 3' XhoI sleC no stop corr 
GCACTCGAGAATTAAAGGATTTAAAGAAGCTATTCT
AGT 
464 5' S461A SOE 
AGTGGAGCATTAACTGGAACTGCCATGGCTACACCT
CATGTTACA 
465 3' S461A Roes 
TGTAACATGAGGTGTAGCCATGGCAGTTCCAGTTAA
TGCTCCACT 
502 5' QTQ/AAA cspBA SOE 
GAATTTATAGAAAAGCCTTTTATATTAGCGGCTGCG
GATGTGCAAAGTTTTTCA 
503 3' QTQ/AAA cspBA Roes 
TTGAAAAACTTTGCACATCCGCAGCCGCTAATATAA
AAGGCTTTTCTATAAATTC 
512 5' NdeI cspB perf ATCC 13124 AGCCATATGGAAAATAAAGCTAAGGTTGGC 
513 3' XhoI cspB perf ATCC 13124 AGCCTCGAGTCTCCTATTAATTAATAATTCCAT 
516 5' S494A cspB perf SOE 
GGATTTGATACTAAAAGTGGTACAGCAATGGCTGCG
CCACAA 
517 3' S494A cspB perf Roes 
TTGTGGCGCAGCCATTGCTGTACCACTTTTAGTATCA
AATCC 
522 5' NcoI cd1433 start AGCCCATGGCAGTGATTTACATGCCAAATTTGCCA 
523 3' XhoI cd1433 no stop AGCCTCGAGGAATTGCCCATAAATACCTTC 
524 5’ NdeI cspC 
AGCCATATGGAAAAATCTTATTGTATAATTTATCAAG
GT  
525 3’ XhoI cspC no stop AGCCTCGAGGAATTGCCCATAAATACCTTC 
532 3' Universal EBS CGAAATTAGAAACTTGCGTTCAGTAAAC 
533 5' EBS2 cspBA 81 
TGAACGCAAGTTTCTAATTTCGGTTGCAATCCGATAG
AGGAAAGTGTCT 
534 3' EBS1d cspBA 81 
CAGATTGTACAAATGTGGTGATAACAGATAAGTCTA
TGATGATAACTTACCTTTCTTTGT 
535 5' IBS1 cspBA 81 
AAAAAAGCTTATAATTATCCTTAATTGCCTATGATGT
GCGCCCAGATAGGGTG 
536 5' CDEP692 GTAAATTCAGATTCTCGGC 
537 5' CDEP1070a AAACGTATAAATTAGGAGGG 
538 3' CDEP1138 TTCCGCTGGCAGCTTAAGCA 
641 5' IBS1 sleC 128a 
AAAAAAGCTTATAATTATCCTTACATTACTTCTTAGT
GCGCCCAGATAGGGTG 
642 3' EBS1d sleC 128a 
CAGATTGTACAAATGTGGTGATAACAGATAAGTCTT
CTTAGGTAACTTACCTTTCTTTGT 
643 5' EBS2 sleC 128a 
TGAACGCAAGTTTCTAATTTCGGTTTAATGTCGATAG
AGGAAAGTGTCT 
665 3' XhoI cspC cd2246 + TAA ACAAGCTCGAGCTATAGAGTATTTGCTATCTGTTG 
668 5' NcoI cspB perf ATG AAAGTCCATGGAAAATAAAGCTAAGGTTGGC 
670 5' NdeI cspB perf ∆96 
AAATGCATATGGCTTATGATAGTAATAGAGCATCAT
GC 
671 3' XhoI 6His cspB perf 
AATACTCGAGTTAGTGGTGGTGGTGGTGGTGTCTCCT
ATTAATTAATAATTCCATTGTTC 
691 5' NotI cspBA cd2247 upstream 
AGAATGCGGCCGCTTCAATTAATTATTGGTATCAAAC
TCAAAG 
701 3' SalI cspB perf pro TAA 
AAATGGTCGACTTATGATGTATATAAAATTTTGGGTA
GCTC 
702 3' SalI cspBA diff pro TAA 
AAATGTCGACTTACTGAGTCTGTAATATAAAAGGCTT
TTC 
703 5' NcoI cspC perf TTTACCATGGAAACTGTATCTAATAAAGCG 
704 3' SalI cspC perf pro TAA AAATGTCGACTTAACTTAGAGTATATATTCCTCCGAG 
709 5' cspB perf K91D SOE 
CTTCAATATATAGAGCTACCCGATATTTTATATACAT
CAGCTTATGATAG 
  84 
710 3' cspB perf K91D Roes 
CTATCATAAGCTGATGTATATAAAATATCGGGTAGCT
CTATATATTGAAG 
717 5' cspB perf ∆jelly SOE 
GGGAATGAAGGTAATAGTGCT|TCTGTTTATAATACC
TTAGGAATCCCT 
718 3' cspB perf ∆jelly Roes 
AGGGATTCCTAAGGTATTATAAACAGA|AGCACTATT
ACCTTCATTCCC 
740 5' cspB perf YTS/AAA SOE 
CAATATATAGAGCTACCCAAAATTTTAGCGGCCGCA
GCTTATGATAGTAATAGAGCATC 
741 3' cspB perf YTS/AAA Roes 
GATGCTCTATTACTATCATAAGCTGCGGCCGCTAAA
ATTTTGGGTAGCTCTATATATTG 
745 5' cspBA DIFF ∆jelly SOE 
GCTGGAAATAATGCAGATAAAGGA|ACTCAAGAGCTT
ACTGTAACAGCT 
746 3' cspBA DIFF ∆jelly Roes 
AGCTGTTACAGTAAGCTCTTGAGT|TCCTTTATCTGCA
TTATTTCCAGC 
753 5' NdeI cspB perf jellyroll AAATCATATGGCTCATCATGTAGGGGGCAAG 
754 3' XhoI cspB perf jellyroll 
AAGACTCGAGTGGTTGTAAAAATCTTGTTCTTTCATT
TAATCC 
765 5' R231E cspB perf SOE 
GCCTTAAGTACACAGCTTATGGAAGGTTTAAAATTTT
TAATGGATAAAAGTAATG 
766 3' R231E cspB perf Roes 
CATTACTTTTATCCATTAAAAATTTTAAACCTTCCAT
AAGCTGTGTACTTAAGGC 
771 3' SalI cspB perf pro 92aa TAA 
AATAGTCGACTTAAATTTTGGGTAGCTCTATATATTG
AAG 
772 3' SalI cspB perf pro 93aa TAA 
AATAGTCGACTTATAAAATTTTGGGTAGCTCTATATA
TTGAAG 
773 5' cspB perf ∆YTS SOE 
CTTCAATATATAGAGCTACCCAAAATTTTA|GCTTATG
ATAGTAATAGAGCATC 
774 3' cspB perf ∆YTS Roes 
GATGCTCTATTACTATCATAAGC|TAAAATTTTGGGTA
GCTCTATATATTGAAG 
818 5' R231Q cspB perf SOE 
GCCTTAAGTACACAGCTTATGCAAGGTTTAAAATTTT
TAATG 
819 3' R231Q cspB perf Roes 
CATTAAAAATTTTAAACCTTGCATAAGCTGTGTACTT
AAGGC 
820 5' E35R cspB perf SOE 
TCCCCTAATAATGGAGAGATACGGTTAGTTGTTTTAT
ATGGAGATAATTTTTTAAG 
821 3' E35R cspB perf Roes 
CTTAAAAAATTATCTCCATATAAAACAACTAACCGT
ATCTCTCCATTATTAGGGGA 
822 5' E59A cspB perf SOE 
GATGTCATAGGTGCTAAAGTTGCAGATTTAGGATAT
GGATTTGGAATAC 
823 3' E59A cspB perf Roes 
GTATTCCAAATCCATATCCTAAATCTGCAACTTTAGC
ACCTATGACATC 
864 3' cspBA KpnI 2775-2751  TGCTAGGCTACTGGTACCTAAAGAC 
868 5' S96R cspB perf SOE 
GAGCTACCCAAAATTTTATATACACGAGCTTATGAT
AGTAATAGAGCATCATGC 
869 3' S96R cspB perf Roes 
GCATGATGCTCTATTACTATCATAAGCTCGTGTATAT
AAAATTTTGGGTAGCTC 
950 5' cspBA Q66+TAG RBS ATG 
GACTCAGTAGGAGGGATTTATGGATGTGCAAAGTTT
TTCAAGTACAGG 
951 3' cspBA Q66+TAG RBS Roes 
AAATCCCTCCTACTGAGTCTGTAATATAAAAGGCTTT
TCTATAAATTCAATTTC 
952 5' E35Q cspB perf SOE 
TCCCCTAATAATGGAGAGATACAGTTAGTTGTTTTAT
ATGGAGATAATTTTTTAAG 
953 3' E35Q cspB perf Roes 
CTTAAAAAATTATCTCCATATAAAACAACTAACTGT
ATCTCTCCATTATTAGGGGA 
   
Restriction enzyme sequences are underlined; point mutations are in bold italics; deletion 
sites are indicated by |.  
  
  85 
 
Table 2.9.S3.: Data collection and refinement statistics. 
 SeMet CspB 
Data collection  
Space group P212121 
Cell dimensions    
    a, b, c (Å) 73.87, 138.17, 140.08 
    α, β, γ  (°)  90, 90, 90 
Wavelength (Å) 0.9794 
Resolution (Å) 50-1.6 (1.618-1.6)* 
Rmerge (%) 7.8 (45.1)* 
I / σI 18.43 (2.05)* 
Completeness (%) 94.66 (70.0)* 
Redundancy 6.6 (2.8)* 
  
SAD Phasing Statistics+  
Selenium sites (ShelX/D) 12 
PATFOM (/D) 24.47 
Overall CC (ShelX/E) (%) 46.27 
Pseudo-Free CC (/E) (%) 81.61 
Contrast/Connectivity (/E) 0.803/0.957 
Final Map CC (/E) 0.936 (0.936)* 
  
Refinement  
Resolution (Å) 43-1.6 
No. reflections 1,332,184 total 
202,733 unique 
Rwork / Rfree 0.15/0.18 
No. atoms 9766 
    Protein 8772 
    Ligand/ion 37 
    Water 957 
B-factors (Å2) 28.6 
    Wilson B 19.1 
    Protein 27.5 
    Ligand/ion 33.5 
    Water 38.2 
R.m.s. deviations  
    Bond lengths (Å) 0.0065 
    Bond angles (°) 0.844 
*Values in parentheses are for highest-resolution shell. 
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CHAPTER 3: TOWARDS AN UNDERSTANDING OF THE SPORE CORTEX 
LYTIC ENZYME IN C. DIFFICILE, SleC 
3.1. Introduction 
Clostridium difficile is a costly and common hospital-acquired infection largely 
due to its ability to form metabolically dormant and resistant spores. These spores are able 
to survive harsh cleaning protocols in place at hospitals and yet remain poised to 
germinate as soon as the proper environment is detected in the form of specific bile 
salts[55].  
The spore consists of the spore core, the innermost layer, which is composed of the 
dehydrated components necessary to form a vegetative cell- the genetic material, 
ribosomes, enzymes, etc. For a figure illustrating the components of C. difficile spores, 
turn to Figure 1.6.2 for electron micrographs, or 1.6.3 for a cartoon depiction. Outside of 
the spore core is a membrane, called the germ cell wall, which will become part of the cell 
wall of the new vegetative cell formed of the spore core when germination is complete. 
The spore cortex, outside of this inner membrane, consists of loosely cross-linked 
peptidoglycan residues[137]. It is the spore cortex that maintains metabolic dormancy by 
acting as a mechanical barrier to water and other small molecules, and keeping the core 
dehydrated; thus, the cortex is critical for maintaining spore resistance[64]. Outside of the 
cortex there is an additional membrane and a proteinaceous spore coat. In some 
Clostridiales and Bacillales species, including C. difficile, there is a loose-fitting 
exosporium, outside of the coat, thought to be involved in resistance, adhesion to surfaces, 
and interactions with the host[58, 138]. 
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As the spore cortex physically enforces spore dormancy in every spore-forming 
bacterium, there are necessarily enzymes commonly called Spore Cortex Lytic Enzymes 
(SCLEs), which are able to digest the spore cortex peptidoglycan during germination. 
Without degradation of the cortex, there is no germination or hydration, and therefore no 
vegetative cell. Conversely, if cortex degradation is initiated at the wrong time, the spore 
will lose the cortex and the resistance it confers. Finally, if SCLEs were active against 
vegetative cell wall peptidoglycan, they could cause lysis of the outgrowing or vegetative 
cells. Therefore, these enzymes need to be tightly regulated, act only on specific cortex 
peptidoglycan residues, and only upon response to a germination signal. 
In Bacillus subtilis, the model organism for spore formation and germination, there 
are three types of enzyme activity that must be accounted for: N-acetylglucosaminidases, 
lytic transglycosylases, and amidases[139]. Each of these has specificity for a particular 
bond found uniquely within the spore cortex peptidoglycan structure (see Figure 3.5.1.). 
SCLEs from both Bacillus and Clostridium require the presence of the muramyl-δ-lactam 
residue binding within the catalytic cleft in a specific position relative to the scissile 
bond[140]. This requirement provides specificity for spore cortex peptidoglycan and 
prevents SCLEs from hydrolyzing vegetative cell wall peptidoglycan, which does not 
contain muramyl-δ-lactam[141]. In Bacillus sp., two such SCLEs are SleB and CwlJ, and 
either is sufficient for complete spore cortex degradation[56]. Though C. difficile appears 
to have homologues to SleB and CwlJ, they are not necessary for germination, and little is 
known about how they function[88]. In C. perfringens, there are only two known SCLEs: 
SleC and SleM, and only SleC is required for germination[89]. In C. perfringens, SleC is 
expressed in the sporulating cell and remains as an inactive zymogen until needed (see 
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Figure 3.5.1)[65]. SleC, which is released into the medium by germinating spores[142], 
has two pre-sequences that are cleaved during sporulation, both a 125 amino-acid N-
terminal sequence called the predomain, and a much smaller C-terminal sequence, 
flanking 3 interior divisions: the propeptide (approximately, amino acids 125-155), the 
catalytic SleC domain (amino acids 156-336), and the peptidoglycan binding domain 
(amino acids 337-423) (see Figure 3.5.1). Although the significance of the processing of 
the C-terminal sequence is not known[67], the N-terminal predomain functions as an 
intramolecular chaperone and is essential for proper folding of SleC[69]. After cleavage of 
the N-terminal predomain, the inactive zymogen, pro-SleC, remains inactive in the 
dormant spore until a germination-specific subtilisin-like serine protease, CspA, CspB, 
and/or CspC, removes the propeptide sequence in response to germinant. Although many 
clostridial species encode multiple Csps, we showed in Chapter 2 that CspB alone is 
sufficient for proteolytically activating pro-SleC[70].  
The spore cortex in C. difficile is made up of three types of peptidoglycan residues: 
N-acetylglucosamine (GlcNAc), N-acetylmuramic acid (MurNAc), and muramic acid δ-
lactam[140]. SleC is predicted to be a monofunctional and processive lytic 
transglycosylase[139], acting on the bond between MurNAc and GlcNAc[140], in contrast 
to the C. perfringens SleC, which is bifunctional as both a lytic transglycosylase and an 
amidase[143]. Spore cortex peptidoglycan is composed of alternating GlcNAc and 
MurNAc residues, where every alternate MurNAc is substituted with muramic acid δ-
lactam[140]. Crosslinking occurs between peptide chains off of muramic acid δ-lactam 
residues on adjacent strands to a total of only about 3% (in contrast to vegetative cell wall, 
which is about 20-30% cross-linked)[140]. Aside from a paper by Christopher Reid’s 
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group that found that C. difficile SleC does not require proteolytic activation for activity 
against B. subtilis cortex peptidoglycan in vitro[139], little is known of the differences in 
the processing and function of SleC in C. difficile compared to C. perfringens. A recent 
paper suggests that C. perfringens is not a good choice of model for understanding C. 
difficile germination, since C. difficile should be re-classified as Peptoclostridium difficile, 
while C. perfringens is correctly classified as a Clostridium sp. The two have more 
divergently-evolved germination pathways than previously thought (see Figure 1.6.4 for 
the previous classification (C. difficile) and proposed reclassification (P. difficile))[75]. 
Additionally, unpublished evidence from our own lab suggests that C. difficile SleC does 
not remain associated with the cleaved predomain or require cleavage of the predomain 
prior to activation of the zymogen (as C. perfringens SleC does[69]). However, the 
predomain is still required for proper folding of SleC in our hands, similar to C. 
perfringens[69]. In contrast with the in vitro analyses of Gutelius et al., we presented in 
Chapter 2 that pro-SleC cleavage in C. difficile is positively correlated with germination 
efficiency[76]. In this same chapter we demonstrated that the predomain processing 
happens in SleC difficile as it does in C. perfringens, prior to incorporation into spores 
(see Figure 2.7.1). 
To understand more about SleC from C. difficile, we sought to determine its 
crystal structure. To this end, we generated multiple expression constructs to identify the 
best construct for crystallization as well as to assess the role of the pro-peptide in 
regulating SleC folding. PONDR disorder-prediction software suggests that SleC is 
moderately disordered, especially in the predomain, and the transition between SleC 
hydrolase domain and substrate binding domain (see Figure 3.5.2.)[144-146]. POODLE, 
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another disorder predicting site, gave similar results[147]. PONDR’s algorithm considers 
the amino acid sequence in a 9-amino-acid window around a particular residue to predict 
order or disorder, and other predictors of order and disorder operate in a similar way, so it 
is possible that the predomain is much more ordered in the context of the rest of the 
sequence. The other large spike of disorder is predicted to occur around residue 350, near 
the N-terminus of the peptidoglycan-binding domain. It is possible that a flexible loop 
separates the peptidoglycan-binding domain from the hydrolase domain; this loop could 
function to optimize binding of the PGB domain to its substrate. The presence of a flexible 
loop would likely result in this prediction of disorder. Structures of similar enzymes from 
Bacillus have not included the peptidoglycan-binding domain; indeed, only the catalytic 
domain of SleB has been crystallized[141, 148].  
 
3.2. Materials and Methods 
3.2.1. Constructing SleC constructs for expression in E. coli.  
Strains generated are illustrated in Figure 4.5.1, and listed in Table 3.6.1. The 
generation of a SleC construct containing a TEV cleavage site would allow us to carry out 
protein expression and folding using the complete sequence and the predomain cleaved off 
after protein purification with the TEV protease. The TEV cleavage site consists of the 
amino acid sequence Glu-X-X-Tyr-X-Gln-Gly/Ser, where the X’s can represent a range of 
different amino acids and cleavage occurs between Gln and Gly/Ser[149]. We used 
ENLYFQG, inserted in between the pre- and pro- domains.  
We used strain #965 to explore the role of the propeptide of SleC in expression 
and solubility. To generate strain #965, we used splicing by overlap extension (SOE) PCR 
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to remove the sequence encoding the 33 amino acids (122-156) of the propeptide. First, 
the N terminal region was amplified using primers #461 and #1090 (see Table 3.6.2 for a 
list of primers and sequences), and the C terminal portion was amplified using primers 
#1089 and #463. The primers were constructed such that the 3’ primer of the N-terminal 
amplicon primer contained a 30 amino acid overlap with the 5’ primer for the C-terminal 
region- the overlap was designed so that the propeptide was missing and the overlap 
occurred on the domain immediately N or C terminal to it. Then, the SOE PCR was 
carried out using the amplified DNA from the first two reactions, and the 5’ and 3’ 
primers of the first reaction and second reaction, respectively, #461 and #463. The 
resulting amplified DNA encoded amino acids 1-122 ligated to 156-423. This was 
digested with NdeI and XhoI, ligated into pET22b, and transformed into DH5α, the 
resulting plasmid was transformed into BL21(DE3) for protein expression. 
We used strain #933 to explore the ‘active’ SleC construct, that is, the form of 
SleC that exists in germinating spores and carries out the hydrolase activity. To create 
strain #933, carrying a construct encoding amino acids 156-423, containing the hydrolase 
domain as well as the peptidoglycan binding domain, primers #636 and #463 were used. 
Strain #933 was subsequently used to provide plasmid for multiple strains, see below. 
To learn more about the hydrolase domain in the absence of the other domains, we 
used strain #967. This strain, carrying a construct with amino acids 156-336 (the 
hydrolase domain only), was generated as above, using primers #636 and #477. 
To explore constructs that could be purified away from the predomain and 
propeptide, we created the following strains. To create strain #1003, carrying the region 
encoding amino acids 1-156 co-expressed with amino acids 156-423, the plasmid isolated 
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from strain #986 (primers #469 and #1076, ligated into pET28a) was used to express the 
predomain and propeptide, and the plasmid isolated from strain #933 (primers #636 and 
#463, ligated into pET22b) was used to express the hydrolase and substrate binding 
domains. Strain #1004 was created in the same manner, carrying the hydrolase and 
substrate binding domains, using plasmid isolated from strain #933, co-expressed with 
only empty vector pET28a as a control.  
To create strain #1159, carrying the region encoding amino acids 1-123 co-
expressed with amino acids 156-423 (with the propeptide missing), the plasmid contained 
in strain #485 was used to express the predomain, and the plasmid contained in strain 
#933 for the hydrolase and substrate binding domains. 
 
3.2.2. Protein Purification of His6-tagged proteins.  
For IPTG induction, overnight cultures of the appropriate BL21(DE3) strain were 
diluted approximately 1:500 in  2xYT (5 g NaCl, 10 g yeast extract, 15 g tryptone/L) 
media and grown shaking (225 rpm) at 37°C.  When an OD600 of 0.6-0.9 was reached, 
IPTG was added to 250 µM, and cultures were grown for 12-16 hr at 19°C.   
We found autoinduction improved the amount of protein isolated from cells, and 
thus this protocol was used in nearly all protein expression experiments[150]. For 
autoinduction, the overnight culture of BL21(DE3) was diluted approximately 
1:500−1:1000-fold in 1 liter terrific broth supplemented with 5052 sugar mix to 5 g 
glycerol, .5 g glucose and 2 g lactose per liter of medium. The cultures were incubated at 
20 °C with shaking (at 225 rpm) for the ~60-70 hour growth period. 
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Cells were collected by centrifugation, transferred to a falcon tube for freezing, 
and stored at -20 °C until ready for use. Frozen pellets were allowed to thaw in ice water 
and resuspended in lysis buffer [500 mM NaCl, 50 mM Tris-HCl, pH 7.5, 15 mM 
imidazole, 10% v/v glycerol]. Protease inhibitor (PMSF, phenylmethylsulfonyl fluoride, 
Pierce) was added to resuspended lysates to a final concentration of approximately 
0.1mM. Cells were then lysed by sonication and clarified by centrifugation at 14,000 x g 
for ~50 minutes.  
Cleared lysates were incubated with Ni-NTA agarose beads (Qiagen) at about 4 
mL bead-slurry volume per ~45 g cell pellet for affinity purification with gentle rocking 
overnight at 4 °C. The binding reaction was pelleted by gentle centrifugation, the 
supernatant set aside, and the pelleted Ni-NTA agarose beads were divided into ~8-10 
Eppendorf tubes and washed three times with lysis buffer.  His6-tagged proteins were 
eluted from the beads by the addition of 350 µL high imidazole elution buffer [500 mM 
NaCl, 50 mM Tris-HCl, pH 7.5, 175 mM imidazole, 10% v/v glycerol].  The elution was 
repeated a second and third time; the eluate was pooled, buffer exchanged in anion 
exchange buffer A [150 mM NaCl, 10 mM Tris pH 7.5, 5% v/v glycerol), and 
concentrated to 750 µL. The concentrated sample was pelleted at 13,000 x g for 10 min at 
4˚C prior to loading on an anion exchange column (GE Healthcare). Buffer B (750mM 
NaCl, otherwise as buffer A) concentration was gradually increased throughout the 
protocol from 100% A, 0% B to 0% A, 100% B. 
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3.2.3. Crystallization studies 
For crystallization studies, His6-tagged SleC difficile (for location of His-tag, see 
Figure 3.5.1) constructs were affinity purified as described above, then further purified 
using an anion exchange column (Hi-Trap Q HP, GE Healthcare); buffer A was 150 mM 
NaCl, 10 mM Tris-HCl pH 7.5, 10% v/v glycerol and buffer B was 750mM NaCl, 10mM 
Tris-HCl pH 7.5, 10% v/v glycerol. The resulting single peak fractions were pooled and 
purified protein was concentrated to between 3 and 25 mg/mL depending on solubility of 
purified protein and yields. Protein purity was analyzed by SDS-PAGE followed by 
Coomassie staining (GelCode Blue, Pierce) or a western blot visualized with our own α-
SleC antibody. 
Preliminary crystallization trials were carried out using Crystal Screen (Hampton 
Research) and SleC #464 at 8 mg/ml in hanging-drop vapor diffusion trays. Trays were 
incubated at 12°C and checked daily for signs of crystal growth for the first week and less 
frequently after that. We adjusted the ratio of protein to buffer in the drops, tried both 
sitting drops and hanging drops, changed the size of the drops, and adjusted the pH or 
ionic strength of the mother liquor. These attempts to further optimize crystallization 
results did not demonstrate improvement in crystal growth. 
 
3.3. Results 
3.3.1. Some SleC constructs were more soluble than others. 
Several SleC expression plasmids were constructed (See Figure 3.5.1 for 
schematics of the constructs). The rationale for different constructs was to enable us to 
solve the structures of different forms of SleC. Specifically, comparing the structures of 
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pro-SleC with active SleC (which is missing the propeptide), would allow us to answer 
questions such as: does the propeptide rest in the catalytic cleft to block access by 
substrates when it is present? Another motivation was to visualize the relationship 
between the peptidoglycan binding domain and the hydrolase domain, and to have the 
ability to express, purify, and crystallize a form of SleC without it, especially knowing that 
all of the deposited structures of similar enzymes lack the peptidoglycan binding domain. 
Constructs were expressed in BL21(DE3) cells and were induced with IPTG or 
autoinduction[150]. Autoinduction cultures produced far more protein than did IPTG 
induction and was used more often. The His-tagged constructs were purified on Ni-NTA 
beads followed by an anion exchange column (Hi-Trap Q HP, GE Healthcare). The 
average yield varied widely, as some constructs could not be purified in any appreciable 
amount while others expressed and purified with good yields (see Figure 3.5.1 for relative 
solubility of each construct). A good yield for C. difficile SleC was about 20 mg of protein 
for 1 liter of autoinduction culture. Soluble SleC was concentrated to about 25 mg/mL 
prior to crystallization trials. 
 
3.3.2. The predomain is essential for proper folding of SleC 
In our studies, we found that the predomain was essential for proper folding and 
solubility. Without the predomain, relative expression was poor, suggesting that the 
protein was improperly folded and degraded or in the insoluble fraction. Similar results 
were found with SleC from C. perfringens by Okamura and colleagues in 2000[69]. While 
Clostridium perfringens and Peptoclostridium difficile are actually quite distantly 
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related[75], our results suggest that the regulation of the SCLE may be similar, with the 
predomain functioning as an intramolecular chaperone necessary for folding. 
We were able to determine that the predomain does not have to belong to the same 
peptide chain in order to carry out its chaperone function. Separate peptides containing the 
predomain and the pro-SleC domains were still able to produce reliable protein expression 
levels. See Figure 3.5.1 to see the co-expressed strains #464 (pre/pro-SleC-PG), #1003 
(pre-pro/SleC-PG), #1159 (pre/SleC-PG), and #1038 (pre-pro/SleC), #1160 (pre/SleC), 
and #1161 (pre/pro-SleC) featuring the co-expressed predomain. We found a slight 
increase in protein yield when the propeptide was associated with the hydrolase instead of 
the predomain (compare #464, #495 (both are pre/pro-SleC-PG), and #1161 (pre/pro-
SleC) versus #1038 (pre-pro/SleC) and #1003 (pre-pro/SleC-PG) in Figure 3.5.1). Because 
activation of SleC requires cleavage of the propeptide, perhaps the orientation of the 
propeptide when it is associated with the hydrolase serves to stabilize the enzyme. Indeed, 
the best expression in trans constructs was observed in those in which the predomain was 
co-expressed and the propeptide was associated with the hydrolase domain. 
 
3.3.3. TEV construct to allow post-purification cleavage of the SleC predomain 
In the case of strain #626, we created a recombinant SleC in which the predomain 
was separated from pro-SleC by a TEV cleavage site insert. Thus, we could purify full 
length protein and separate the predomain (predicted to be disordered) before attempting 
to crystallize the protein, while having the benefit of the predomain for expression and 
preliminary purification steps. We were unable to see protease cleavage of this construct, 
although the TEV protease was active. We suspect that either a) the location of the 
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recognition sequence was buried and inaccessible or b) the absence of a linker region 
flanking either side of the sequence led to improper secondary structure, influenced by the 
local structure of SleC, and thus a lack of recognition by TEV or steric occlusion of the 
scissile bond. 
 
3.3.4. Presence of the peptidoglycan binding domain has little impact on expression 
levels 
We found that the presence or absence of the peptidoglycan binding domain did 
not impact the expression levels of our recombinant SleC constructs. In Figure 3.5.1, the 
relative expression levels of pre/pro-SleC constructs such as #1161, and pre/pro-SleC-PG 
constructs such as #464 and #495 were approximately the same. The substrate binding 
domain serves to position the enzyme in relative proximity to the substrate, but could be 
located distant from the catalytic domain, so perhaps the expression of SleC is 
independent of the presence or absence of the peptidoglycan binding domain. 
 
3.3.5. Crystallization attempts were unsuccessful 
The recombinant constructs that were promising in expression and purification 
steps (full-length wild-type SleC, #495, #464 and #1003) were used in crystallization trays 
using pre-formulated kits of reagents available from Hampton Research. We found that all 
of the constructs gave very similar results and formed shiny clusters in a great variety of 
conditions (Figure 3.5.5). However, despite repeated attempts to improve on these initial 
hits, we were never able to progress past this stage or obtain any different crystalline 
morphology. Crystal clusters were present in all of the following conditions: 0.2M 
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ammonium sulfate, 30% w/v PEG 8000; 4M sodium formate; 0.1M sodium acetate 
trihydrate pH 4.6, 2M sodium formate; 0.5M sodium chloride, 0.01M magnesium chloride 
hexahydrate, 0.01M hexadecyltrimethylammonium bromide; 35% v/v 1,4-dioxane; 0.2M 
potassium thiocyanate, 20% PEG 3350; and 0.2M ammonium sulfate, 20% PEG 3350. 
 
3.4. Discussion 
The expression data suggest that the predomain serves as an intramolecular 
chaperone, essential for proper folding, in C. difficile as has been shown in C. 
perfringens[69]. The data we have gathered so far on the propeptide could support a role 
in stabilizing the catalytic domain of SleC, in addition to the evidence that this propeptide 
needs to be removed in C. perfringens in order to activate the enzyme. It is possible that 
the propeptide sterically occludes access to the catalytic cleft from possible substrates. 
A recent paper by Christopher Reid’s group represents the best data besides our 
own data (presented in Chapter 2) about SleC regulation in C. difficile[139]. In this paper, 
Gutelius and colleagues referred to SleC with different descriptions for the domains that 
we have used in our own data. The domains they included consisted of an N-terminal 
region comprising amino acids 1-292 with no known function, a SpoIID/LytB domain 
between amino acids 293-341 containing the catalytic cleft, and the peptidoglycan binding 
domain between residues 342 to 423, similar to the boundaries of our own peptidoglycan 
binding domain. Contrary to our data showing that CspB processing of SleC is required 
for SleC activity in vivo, Gutelius and colleagues found that in vitro the activity of SleC 
does not depend on previous processing by germination-specific proteases such as 
CspB[139]. However they did not determine if this processing would increase SleC’s 
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catalytic efficiency. It is possible that this discrepancy between our results and theirs is 
entirely due to the differences between in vitro and in vivo processes. Gutelius et al. also 
observed that the absence of the peptidoglycan binding domain did not prevent activity, 
but rather slowed it down, suggesting that this domain functions as a processivity factor, 
but is not required for catalytic activity or binding of SleC to substrate[139]. 
We found SleC to be difficult in all aspects of experimentation— recombinant 
constructs often were poorly expressed and difficult to purify in sufficient amounts needed 
for crystallographic assays. Additionally, we were unable to obtain crystals of SleC 
despite repeated attempts to optimize plentiful preliminary hits. Perhaps the PONDR plot 
says it all— SleC is disordered and not a good target for crystallization studies (Figure 
3.5.3 for disorder plot, Figure 3.5.5 for crystallization results). However, there is still 
much to learn about how the only known SCLE functions in C. difficile and structural data 
could play an important role in our understanding of the function of the individual 
domains of SleC. If the full-length enzyme could be crystallized, would we see the 
predomain as a sort of scaffold upon which the rest of the enzyme is built, similar to the 
propeptide intramolecular chaperone in CspB perfringens? Could we see the mechanism 
by which the propeptide prevents catalytic activity indicated by the structure, and find the 
propeptide draped across the catalytic cleft, blocking access to would-be substrates? Does 
the peptidoglycan domain rest apart from the catalytic core of the enzyme as a 
processivity factor, or is it positioned near the catalytic cleft to directly link substrate with 
active site? 
There is much more to be learned about SleC, and perhaps the way forward 
consists of more patience in crystallization trials or identification of more unique 
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crystallization conditions (high salt or chaotropic agents). Another option, as we found 
helpful with CspB, would be to switch organisms to find a protein that will be more 
amenable to crystallization. We have previously tried SleC (full length) from C. 
perfringens in crystallization attempts without success. If that method is to be used, we 
have more guidance on the best options for related species due to proposed reclassification 
of some Clostridium spp. as Peptoclostridium spp., including Clostridium bifermentans or 
sordellii[75]. 
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3.5. Figures 
 
Figure 3.5.1. Schematic illustrating the SleC constructs designed for crystallization. 
Schematic showing different C. difficile SleC constructs designed for expression in 
E. coli. Predomain is drawn in blue, propeptide in purple, SleC hydrolase domain in light 
green, and peptidoglycan binding domain in dark green. A gap between domains indicates 
that these were co-expressed from separate plasmids. The 6-His tag for purification 
purposes is shown as a red line, and the TEV protease cleavage site is denoted by a 
lightning bolt. Relative expression levels to full length SleC is indicated with + or – signs. 
  102 
Strains #464 and #495 (pre/pro-SleC-PG) are similar to the native form of SleC found in 
C. difficile spores, with the understanding that the predomain does not appear to be 
associated. Strains #464 and #495 closely represent the form of SleC observed by others in 
C. perfringens, with the predomain cleaved but remaining noncovalently associated with 
the pro-SleC form. 
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Figure 3.5.2. Schematic illustrating the three forms of SleC relevant to C. difficile spore germination. 
The illustration shows the three relevant forms of SleC, as discussed in the text. 
Full length SleC is only present in sporulating cells, but in mature spores, the second form 
is present, having had the predomain processed away. This form is autoinhibited by the 
presence on the propeptide. The third and final form, active SleC, has had the propeptide 
cleaved off and is an active hydrolase.  




Figure 3.5.3. PONDR prediction of ordered and disordered regions for full-length C. difficile SleC 
Prediction of ordered and disordered regions in full length C. difficile SleC. A 
segment of protein with a PONDR score greater than 0.5 is expected to be disordered; 
with a score less than 0.5 it is more likely to be ordered. The black bar at the midline in 
the prediction for the predomain illustrates that this region is predicted to be highly 
disordered for about 50 residues. A disordered protein is less likely to be amenable to 
crystallization. 
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Figure 3.5.4. Strain #495 (pre/pro-SleC-PG) coomassie gel illustrating SleC construct NiNTA 
purification process 
Strain #495 (pre/pro-SleC-PG) coomassie gel illustrating SleC construct 
purification. Construct #495 includes a 6His tag on both the pro-SleC-PG and the 
predomain, and leads to a high yield of the predomain copurifying with pro-SleC-PG. 
#495 pro-SleC-PG was very soluble, and purified nicely.  
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Figure 3.5.5. SleC crystallization trials. 
Representative results of the most promising hits obtained for the SleC 
crystallization. These results occurred in a wide variety of crystallization solutions but 
could not be further improved. Condition shown is 400mM KCl, 12% PEG 3350. Upper 
right panel shows a zoomed-in version of the same image. Drops were 1 µL protein and 1 
µL reservoir, for a starting size of 2 µL, and filled with soft crystalline phasing. 
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3.6. Tables 
 
Table 3.6.1. Strains and plasmids used in SleC studies. 
Strain 




464 Pre/ pro-SleC-PG-6His pET22b/pET28a  
626 Pre-TEV-pro-SleC-PG-6His pET21a  
965 Pre-SleC-PG-6His pET22b  
933 SleC-PG-6His pET22b  
967 SleC-6His pET22b  
1003 Pre-pro/ SleC-PG-6His pET28a/pET22b  
1004 SleC-PG-6His with empty vector pET22b/empty pET28a  
1159 Pre/ SleC-PG-6His pET28a/pET22b  
495 6His-Pre/ pro-SleC-PG-6His pET28a/pET22b  
1038 Pre-pro/ SleC-6His pET28a/pET22b  
1160 Pre/ SleC-6His pET28a/pET22b  
1161 Pre/ pro-SleC-6His pET28a/pET22b  
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Table 3.6.2. Primers used in SleC studies. 
 
# Name Sequence 
461 5' NdeI sleC 
AGCCATATGCAAGATGGTTTCTTAACAGT
AAGC 
463 3' XhoI sleC no stop corr 
GCACTCGAGAATTAAAGGATTTAAAGAA
GCTATTCTAGT 
469 5' NcoI sleC GGA start 
AGCCCATGGGACAAGATGGTTTCTTAACA
GTAAGC 
477 3' XhoI sleC 334 aa no PG 
GCACTCGAGTGACACTGGTACACCACTTA
C 
636 5' NdeI sleC activated 156 aa 
AAATCATATGGTATTAGATAACCCTGTAG
TG 
1076 3’ XhoI sleC REV 
AAGCCTCGAGTTAAACGAAACCAGTAGG
AGGAGG 
1089 5' sleC ∆122-155aa SOE 
GCGTTCTTTCTCAAGACAAAGTGTATTAG
ATAACCCTGTAGTGCC 
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CHAPTER 4: C. BIFERMENTANS CspC IS MORE AMENABLE TO 
CRYSTALLIZATION THAN IS CspC FROM C. DIFFICILE 
4.1. Introduction 
Like all spore-forming bacteria, C. difficile requires a signal to initiate 
germination. Spore forming bacteria germinate by sensing small molecule germinants, 
which vary with strain and species, using specific germinant receptors. Much of what is 
known about spore germination is from Bacillus subtilis, the model organism for spore 
forming bacteria, while other studies have been done with C. perfringens. In most cases, 
germination begins with a ger receptor sensing its cognate germinant, leading to activation 
of the cortex lytic enzymes[29, 56, 87]. For C. difficile, it has been known that bile salts 
induced germination; however, it was not known how C. difficile sensed these germinants, 
as it lacks the ger family of receptors that are used in other species[56, 85]. Additionally, 
PrkC has been shown to initiate germination of B. subtilis in response to cortex 
peptidoglycan fragments, and while the C. difficile genome contains a homologue of prkC, 
it seemed unlikely that the same receptor could respond specifically to such different 
substrates as peptidoglycan and bile salts[74, 151]. 
The germination process in C. difficile has remained relatively poorly understood 
in contrast with the processes in C. perfringens and B. subtilis. In the 1980s it was 
discovered that bile salts played an important role in C. difficile spore germination[49], 
and by 1987, evidence suggested that taurocholate was the preferred bile acid[73]. Still, it 
was not known if there were specific receptors for the germinants until 2010, when 
Ramirez and colleagues demonstrated that the kinetic profile of germination of C. difficile 
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spores strongly suggested the use of a receptor-mediated mechanism as opposed to 
physical membrane-permeabilization[74].  
Joseph Sorg and colleagues published in 2008 that taurocholate and glycine were 
co-germinants[55], and discovered that chenodeoxycholate was a competitive inhibitor of 
the taurocholate germinant[50, 51, 152]. Having championed the effort to discover the 
germinant receptor for C. difficile, in 2013 Sorg and coworkers identified the taurocholate-
binding germinant receptor in C. difficile, CspC, a subtilisin-like serine pseudoprotease 
whose function was previously unknown[47]. The Csp proteases are conserved in the 
Clostridia and function in germination. In C. perfringens, it has been shown that CspB is 
necessary for the cleavage and activation of SleC, the germination hydrolase[70].  
However, only one of the Csps, CspB, has an intact catalytic triad in C. difficile, and this 
is also found in other members of the Peptostreptococcaceae family to which C. difficile 
belongs, such as C. sordellii and C. bifermentans.  
CspB from C. perfringens, as discussed in chapter two, is a subtilisin-like serine 
protease. The subtilisins are a large family of processive and nonspecific proteases, that 
require cleavage of the prodomain, which functions as an intramolecular chaperone, in 
order to gain activity[153]. In CspB perfringens, the prodomain remained associated with 
the catalytic domain in our structure, which could be a way for CspB’s activity to be 
limited to germination[76]. CspA and CspC are also expected to adopt subtilisin folds, 
though in C. difficile their catalytic triads are not intact and as such they would be unable 
to function as proteases[76]. Interestingly, a random mutagenesis screen carried out by 
Francis and colleagues revealed that germination-null mutants primarily had point 
mutations in CspC[47]. When these point mutations were mapped to our structure of CspB 
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(see Figure 4.5.2), we found that most cluster right around the active site and are in highly 
or strictly conserved residues. In most cases, the presence of the mutation would cause 
steric clashing with nearby chains of the protein and disrupt the fold (see Figure 4.5.2). 
Only on two occasions, with a stop codon generated at the C-terminus of the CspA 
domain of CspBA, and one generated in the middle of the CspB domain, did the 
inactivating point mutation fall outside of CspC. Given the importance of CspB protease 
function in SleC activation (Chapter 2), the identification of null mutations in CspBA was 
not as surprising as the mutations in CspC, which lacks catalytic function. Another 
interesting result from this group identified a gain-of-function mutant that germinated in 
response to chenodeoxycholate, which functions as an inhibitor for wild type C. 
difficile[47]. The single residue mutation that enabled the gain of function mapped to the 
dimer interface we observed in our CspB crystal structure (see Figure 4.5.6). As CspC is 
expected to have the same overall fold as CspB, it is possible that the CspB/CspB dimer 
we observed in the crystals could translate to a CspC/CspB dimer in vivo, perhaps 
explaining how CspC, sensing germinant, relays this signal to CspB, though we do not yet 
have any evidence for this idea. 
The function of CspA during germination is still not known, but preliminary data 
from Joseph Sorg’s group, as mentioned above[47], and our own unpublished 
observations indicate that it is also required during germination. We sought to determine 
the structure of CspC to learn more about how it binds germinants and how it may act to 
signal downstream constituents such as CspB. 
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4.2. Materials and methods 
4.2.1. C. difficile CspC protein expression 
 
CspC from C. difficile was expressed in E. coli BL21(DE3) cells from a pET22b 
plasmid using the autoinduction method in Terrific Broth supplemented with 5052 sugar 
mix and ampicillin or carbenicillin with ~60 hour incubation at 20°C[150]. The CspC 
construct was codon-optimized for expression in E. coli and was fused C-terminally to the 
cysteine protease domain (CPD) from Vibrio cholerae MARTX toxin[154]. 
 
4.2.2. C. difficile CspC protein purification 
Purification was carried out in three steps: immobilized metal affinity 
chromatography (IMAC), induced cleavage of CPD, and a Superdex 200 gel filtration 
column. IMAC was carried out with Ni-NTA agarose beads (5 Prime). The C-terminal 6-
His tag on the CPD binds the nickel beads. Washes were carried out three times with low 
imidazole buffer (MLIB) (500mM NaCL, 10mM Tris-HCl pH 7.5, 10% (v/v) glycerol, 15 
mM imidazole) to decrease non-specific binding to the beads.  
The cysteine protease domain contains auto-cleavage activity in the presence of 
inositol hexakis phosphate (InsP6), which is present in mammalian cells but not found in 
prokaryotes[154]. Therefore, InsP6 was supplied to the culture, inducing cleavage between 
CspC and CPD-6-His and leaving behind a four amino acid VDAL linker C-terminal to 
CspC. InsP6 was added to about 200µM and incubated with gentle shaking at 4°C for 4-6 
hours or overnight. Without the addition of imidazole, the His-tag remained bound to the 
beads, and the CPD with it, leaving untagged CspC released to the supernatant. 
Supernatant was collected and bead washes were carried out three times using MLIB 
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(without supplemented InsP6), and then the cleavage step was repeated, with more InsP6 
added, incubation, and bead washes in MLIB. Supernatants and washes, containing 
untagged CspC, were pooled and gently dialyzed into gel filtration buffer (150mM NaCl, 
10mM Tris-HCl pH 7.5, 10% (v/v) glycerol) overnight. The buffer-exchanged protein was 
concentrated to 20 mg/mL or less, and gel filtration chromatography was carried out using 
a Superdex 200 (GE Healthcare) column, 500 µL injection volume and less than 10 mg of 
protein per run. A typical yield for difficile CspC purification was about 4 mg of purified 
protein per liter of autoinduction culture using the protocol described above[154]. Protein 
was concentrated to about 30mg/mL in gel filtration buffer (described above— shorthand 
150/10/10) or a modified buffer (200mM NaCl, 10mM Tris-HCl pH 7.5, 5% (v/v) 
glycerol—shorthand 200/10/5), separated into small aliquots, flash cooled in liquid 
nitrogen and stored at -80 °C. 
 
4.2.3. CspC bifermentans protein purification 
The cspC gene from a related species, C. bifermentans, was codon-optimized for 
expression in E. coli and synthesized by Genscript. The codon-optimized cspC from C. 
bifermentans fragment was inserted N-terminal to the CPD sequence for expression and 
purification similar to CspC C. difficile. Purification of CspC bifermentans proceeded as 
described above, although the yields were much greater and often required dividing 
purification experiments up into several tubes at once to keep volumes and concentrations 
lower. A typical yield for CspC bifermentans was about 20 mg of purified protein per liter 
of autoinduction culture, about 5 fold greater than the yield of a typical CspC difficile 
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purification. For a figure showing the gels and traces obtained during a purification 
process, see Figure 4.5.4. 
 
4.2.4. CspC crystallization trials 
Purified and concentrated CspC from both C. difficile and C. bifermentans was set 
in preliminary crystallization screens at about 15 mg/mL to assess a wide variety of 
possible crystallization conditions. We used a variety of sparse-matrix crystal screens: 
Crystal Screen, Index, and Peg/Ion primarily (Hampton Research), and Wizard screens I 
and II (Emerald Biosystems). We explored several tray incubation temperatures, 12 °C, 18 
°C, and 24 °C. 
 
4.2.5. CspC bifermentans crystallization optimization 
 
Crystals were discovered a mixture of ammonium acetate and polyethylene glycol. 
Optimization for initial crystal hits required adjusting the pH: with the combination of 
buffer in the protein solution and buffer in the crystallization solution, the final pH was 
about 6, and we found that a pH closer to 8 improved crystal growth. We achieved the 
higher pH by the addition of 1 M BIS-TRIS propane at pH 8.8 in addition to the sodium 
citrate pH 5.6. The ideal concentrations of these buffers seemed to be around 75 µM and 
25 µM respectively, but any combination of the two with a 1:1 ratio or better for BIS-
TRIS propane would reliably produced improved crystals. 
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4.2.6. CspC bifermentans crystal cryoprotection 
 
0.5 µL (1 µL could also be used without consequence) of cryoprotectant solution 
(26% (w/v) PEG 3350, 18% (v/v) glycerol, 200 mM ammonium acetate, 60 mM BIS-
TRIS propane, pH 8.8, 40 mM sodium citrate, pH 5.6) was added directly to a 2 µl drop 
containing crystals to be scooped and frozen, let to rest for at least one minute, and then a 
crystal scooped using a nylon loop and flash cooled in liquid nitrogen. 
 
4.2.7. CspC bifermentans data collection 
 
Data sets for CspC bifermentans were collected at 100K and λ= 0.979 Å at 




4.3.1. Optimization of CspC production in E. coli 
 
We found that using codon-optimized constructs helped with E. coli expressions, 
but the largest difference we found was the addition of the CPD. While it had been shown 
that CPD fusion proteins are sometimes more soluble than the target protein alone[154], 
for CspC it improved our yields (unpublished data). We found that during purification, 
CspC difficile tended to precipitate prior to gel filtration if it exceeded concentrations of 
~2 mg/mL. The gel filtration protocol requires that small volumes of protein be loaded at 
the start of a run, and, due to low concentration, CspC difficile therefore often required 
multiple runs. This issue was not as prevalent with CspC bifermentans, which behaved 
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better during purifications, with better expression levels, a more complete cleavage of the 
CPD tag used during purification, and tolerant of higher concentrations prior to gel 
filtration, in the 15-20 mg/mL range. 
CspC C. bifermentans was a good option for a related species to use for protein, 
because it, like C. difficile, should likely be reclassified as a Peptoclostridium sp.[75], see 
Figure 1.6.4. It contains the same catalytic-triad disruptions as C. difficile CspC and CspA, 
and preliminary data from our lab has also indicated that cspC from C. bifermentans can 




4.3.2. CspC bifermentans performs better in crystallization trials than CspC difficile. 
 
While we did not find any crystalline-like material using CspC from C. difficile, 
we found that CspC from C. bifermentans crystallized more readily, and were able to 
identify spherulites and crystal clusters forming in Crystal Screen HT from Hampton 
Research (See Figure 4.5.3 for PONDR disorder prediction for CspC difficile). The initial 
crystallization conditions for CspC bifermentans were a mixture of ammonium acetate and 
polyethylene glycol. Very small crystals nucleated readily, nucleating off the same point 
and overlapping each other. Crystals grew very slowly, taking three weeks to a month to 
grow large enough for X-ray data collection (see Figure 4.5.5 for initial crystal hits). There 
were frequently multiple crystals fused into a single crystal cluster. If there were crystals 
that appeared to be single crystals, they were smaller and more difficult to tease apart from 
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their multi-crystal counterparts. Most clusters were only ~30 microns prior to optimization 
efforts. 
 
4.3.3. CspC bifermentans crystals nucleate readily and remain small. 
 
We found that checking the trays frequently worsened nucleation. We therefore set 
most trays in duplicate- one to be checked regularly, one to rest undisturbed for at least the 
first week, after which point it was checked only infrequently. This strategy helped us to 
obtain fewer and slightly larger crystals per drop. The best crystals we obtained (Figure 
4.5.5) grew after about 4 months of infrequent checking. 
 
4.3.4. CspC bifermentans crystals require a gentle cryoprotection protocol. 
 
Cryoprotection was challenging for these crystals. We found that the 
cryoprotecting solution had to be added directly to the drop containing the crystals as they 
could not be scooped from their mother liquor and put into another drop containing 
artificial mother liquor supplemented with a cryoprotectant. Glycerol was far superior to 
sucrose, glucose and PEG 400 as a cryoprotective agent for these crystals, but as most of 
the crystals were grown in the presence of very little glycerol (10% present in the storage 
buffer, diluted in the drop to 5%), they required a gentle introduction to the 15% (v/v) 
required for sufficient cryoprotection. Optimization of the cryoprotection protocol was an 
important step for obtaining the best possible data from the CspC crystals, though the 
crystals still contained multiple lattices. 
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4.3.5. Crystals contain multiple lattices, making data processing challenging. 
 
The CspC crystals are small and require long exposures on our copper Kα X-ray 
generator (Rigaku HR300) equipped with a MAR345 image plate detector. Typical 
exposures were at least 20 minutes with 4 times 0.5° oscillations during this time. Data 
could be collected to about 3 Å resolution. The resulting data proved to be highly mosaic 
and frequently contained more than one lattice, making it difficult to process. 
The data acquired at APS beamline 23ID-B extends to 2 Å resolution. The space 
group is most likely C-centered monoclinic with unit cell dimensions a = 169.72 Å, b = 
163.58 Å, c = 102.84 Å. Unit cell angles are α= 86.89°, β= 113.69°, γ= 90.49°. We expect 
four monomers per asymmetric unit, with a Matthews coefficient of 2.6 and a solvent 
content of 53%. While the resolution is improved over that obtained using our home X-ray 






Germination of C. difficile spores takes place in the large intestine[85]. However, 
taurocholate is generally cleaved to its substituents, taurine and cholate, by resident 
bacteria in the large bowel[46, 48]. These two products do not reliably induce germination 
either individually or in combination, though there is some debate on this point [51, 55, 
74, 155]. Taurocholate would be present in higher concentrations in the large bowel of 
individuals with decreased numbers of resident bacteria, such as individuals who have 
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recently undergone antibiotic therapy[48, 156].  The presence of taurocholate in the large 
bowel, therefore, indicates a smaller competing population and a chance for C. difficile 
vegetative cells to find the nutrients they require. 
Additionally, chenodeoxycholate is a known competitive inhibitor of taurocholate-
induced germination[50, 51], and chenodeoxycholate follows an inverse concentration 
relationship to taurocholate: in healthy patients, taurocholate is present in the small bowel, 
but undetectable in the large bowel, having been hydrolyzed into taurine and cholate by 
resident bacteria[46, 48]. Chenodeoxycholate, conversely, is undetectable in the small 
bowel, instead appearing only as a moiety of other compounds such as 
glycochenodeoxycholate and taurochenodeoxycholate[156, 157]. As taurocholate is 
hydrolyzed in the large bowel so, too, is chenodeoxycholate cleaved from conjugated 
amino acids and can then function to inhibit germination[155].  
Therefore, in the large bowel of a healthy individual with many commensal 
bacteria, there would be little to no taurocholate, thus the absence of a germination signal, 
and there would be ample chenodeoxycholate to inhibit germination. In an antibiotic 
treated individual, however, the relative amounts would be reversed and would drive 
germination rather than prevent it. 
Ramirez and colleagues propose that dormant spores may only bind taurocholate, 
the limiting step, at which point subsequent taurocholate moieties would bind more readily 
via cooperativity, though there is no evidence that more than one taurocholate germinant 
may bind the same receptor[74]. Only when activated by the binding of taurocholate, 
would the spores become able to bind glycine, cooperatively until all binding sites are full, 
and begin the germination process[74]. 
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A structure of CspC from C. difficile or the closely related C. bifermentans[75] 
would add invaluable information to the current understanding of how the germination 
process happens in C. difficile and other Peptoclostridium spp, and how it differs from the 
mechanism utilized in C. perfringens and other related Clostridia. A structure in complex 
with taurocholate, or chenodeoxycholate, and glycine would add the valuable 
understanding of exactly how the interaction between receptor and substrates takes place 
and would represent the first crystal structure of a germinant receptor bound to its ligand. 
Accordingly, we have made substantial progress in expressing, purifying, and crystallizing 
CspC and have obtained preliminary crystallographic data towards the structure 
determination of unliganded CspC from C. bifermentans. Further work is needed to 
improve the crystals that grow readily, and obtain larger, single crystals for data 
collection. There are multiple avenues to accomplish this, including the use of detergents 
or additives, use of micro- or macro-seeding, and varying incubation temperatures. The 
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4.5. Figures 
 
Figure 4.5.1. Csp expression schematics 
Schematics illustrating (A) the arrangement of Csp proteases in C. difficile and (B) 
the CspC-CPD fusion generated for purposes of expression and purification. The predicted 
prodomain of CspBA is indicated “Pro?”. Location of catalytic residues and cleavage sites 
are marked.  
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Figure 4.5.2.	  CspC germination-null mutants mapped to CspB structure illustrates clustering around 
active site. 
Single amino-acid substitutions within CspC that rendered Clostridium difficile 
germination null, were aligned with CspB structure from C. perfringens. Almost all of the 
mutations were located near the active site in such a way that they would disrupt the fold 
due to steric clash (mutations shown as black sticks, active site residues of CspB shown as 
yellow sticks; right panel), suggesting that CspC retains the shape of a subtilisin serine 
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Figure 4.5.3. Predictions of Naturally Disordered Regions for CspC from Clostridium difficile 
 
PONDR plot generated for full-length CspC from C. difficile illustrated more 
prediction of order than for SleC (Chapter 3), but containing several short segments 
predicted to be disordered. 
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Figure 4.5.4. CspC bifermentans purification process. 
CspC bifermentans purification process. Top panel, NiNTA beads purification 
illustrating cleared lysates, flow through and washes of beads, addition of IP6 (IP61), 
second IP6 cleavage (IP62), and washes of IP6 cleavages, and finally the eluate showing 
uncleaved CspC-CPD still stuck to beads. Pooled fractions from IP6 cleavages and washes 
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were concentrated and run on Superdex 200 gel filtration column, illustrating trace of pure 
CspC bifermentans, bottom panel.  
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Figure 4.5.5. CspC bifermentans crystal progression 
 
CspC crystallization optimization process, showing progression of CspC crystals. 
All were grown at 18°C. Bottom right panel took four months to grow in a tray that was 
only checked infrequently. 
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Figure 4.5.6. Simplified view of CspB crystallization dimer interface with potential CspC ligand 
binding site shown in blue 
 
CspB was found to dimerize in our crystals, despite evidence it functions as a 
monomer in vitro. It is possible that the dimer interaction observed in the CspB crystals 
represents a dimerization of CspB with CspC in germinating spores. The proposed CspC 
taurocholate binding site as aligned with the CspB structure, highlighted in blue, and 
pointed to by the arrow, suggests a direct communication between CspC + germinant and 
CspB. One CspB monomer is shown in tan, and the other in pink. 
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CHAPTER 5: FUTURE DIRECTIONS 
The germination cascade in C. difficile, based on our current understanding, begins 
with the germination receptor pseudoprotease CspC binding to co-germinants taurocholate 
and glycine, passing the activation signal on to germination protease CspB in a way that is 
not yet understood, resulting in CspB activation of SleC, the cortex hydrolase, which 
begins breaking down the cortex to allow for core hydration and expansion and eventually 
outgrowth to a vegetative, toxin-producing cell. This germination step is common and 
critical to each infection. This area of study is thus of paramount importance, especially 
given the persistence and tenacity of C. difficile infections. See Figure 5.1.1 for a 
schematic of the Csp/SleC cascade required to initiate germination, as we currently 
understand it. 
For a more complete understanding of the germination process, several additional 
studies are necessary. A structure demonstrating the interaction of CspC with germinant or 
inhibitors bound would be illustrative of how this binding may be disrupted. The gain-of-
function point mutation identified by Francis and colleagues which enabled CspC to 
respond to its inhibitor added some insight to this effort[47]. The specific mutation 
required an arginine in place of the glycine in position 457, and in our CspB structure this 
corresponded to a small loop located in the dimer interface. It is possible that this location 
is where taurocholate or chenodeoxycholate would bind, thus potentially identifying the 
method by which CspC and CspB communicate with each other.  
We also need to understand exactly how CspC and CspB interact, and if this 
interaction is transient or involves binding and catalysis. Additionally, it is still unknown 
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if CspC and CspB interact directly or if there are other proteins involved. The dimer 
interface observed in crystallized CspB C. perfringens calls to mind an exciting idea for a 
CspC/CspB dimer, but we do not know if it is relevant and indicative of observations to 
come in C. difficile, or simply a crystal packing coincidence. How does CspC activate 
CspB? We showed in Chapter 2 that CspB from C. perfringens had cleaved but not 
dissociated from its inhibitory prodomain. It is possible that CspB in C. difficile could 
exist in this same inhibited state in spores until activation by CspC, which could trigger 
protease activity against the prodomain, thus exposing the competent active site. 
Similarly, can CspB and SleC be observed binding together? SleC is activated by 
CspB’s cleavage of its inhibitory propeptide, but to see a structure of the two in complex 
would answer so many questions about how this process takes place and help us to 
continue to expand our understanding of the germination process. A SleC mutant that is 
unable to be cleaved (or a CspB mutant that is unable to hydrolyze SleC) would be a good 
place to start to look for these interaction, using pull downs, western blots, dynamic light 
scattering experiments and gel-shift assays, with the addition of a cross-linking compound 
if necessary to try to observe binding between both CspB and SleC, and CspC and CspB.  
An antibody to observe the location of CspA within both sporulating cells and the 
mature spore would be helpful in understanding the role it plays in germination. Similarly, 
pull-down and interaction studies could be carried out using CspA, CspB, and CspC as 
perhaps CspA helps mediate this interaction by acting as a scaffold, and stabilizing the 
complex. We now have evidence that CspA has an important role in germination[47], as 
suggested by its evolutionary conservation, but we do not yet know what that role might 
be. 
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Crystal structures of all complexes would be extremely helpful in furthering this 
field of study. As crystals of protein complexes are often difficult to obtain, several 
truncation constructs could be made of target proteins to observe fragment-binding if 
expression and purification of full-length proteins proves difficult. Design of these 
fragments would be greatly aided by the structures of each protein, so this is of top 
importance. The use of nanobodies to stabilize crystallization-resistant proteins could be 
employed, as this method has proved beneficial in some cases[158, 159].  
Understanding the molecular basis underlying spore germination in C. difficile 
could lead to novel treatments that could block the cycle of infection and reinfection and 
serve to greatly aid in our treatments of this disease. A particularly challenging aspect 
with C. difficile infections relates to its ability to cause recurring infections that increase in 
severity, and current treatments leave a patient more susceptible to reinfection by way of a 
disrupted microbiota, and because the patients typically need to be hospitalized during the 
treatment for the C. difficile infection, thus exposing them to more spores. 
There are two ways to interfere with C. difficile spread and infection from a 
germination perspective. The first way is to block germination, despite the presence of 
germinants and a suitable environment[155]. This method is somewhat complicated, 
requiring either infection by a mutated form of C. difficile or taking by mouth doses of a 
compound that could interfere with the germinant taurocholate or the inhibitor, 
chenodeoxycholate in such a way that favorable germination conditions would go 
undetected by the spores. The second way is to force germination in the absence of the 
suitable environment. Vegetative cells are much more susceptible to cleaning agents and 
disinfection protocols than are spores, as well as being unable to live in the presence of 
  131 
oxygen if one can force outgrowth to vegetative cells in a hospital room, the cells will 
quickly die. This has been done with some success recently[160], and is simpler than 
attempting to interfere with germination in the colon, as C. difficile and the digestive 
process have co-evolved to work together. 
 




Figure 5.1.1. Diagram illustrating the proposed model for germination initiation in C. difficile, 
illustrating protein partners studied in previous chapters of this thesis. 
 
Proposed model for activation of germination in Clostridium difficile spores. CspC 
(pink rectangle) within dormant spore binds to the germinant (yellow circle). CspC relays 
this signal to CspB (blue rectangle), which becomes active upon receiving signal from 
upstream CspC. Active CspB then cleaves pro-SleC (orange circle) into active SleC 
(orange pac-man). SleC hydrolyzes the peptidoglycan cortex of the spore, allowing 
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